<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39476401</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1665-1731</ISSN><JournalIssue CitedMedium="Internet"><Volume>94</Volume><Issue>Supl 3</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Archivos de cardiologia de Mexico</Title><ISOAbbreviation>Arch Cardiol Mex</ISOAbbreviation></Journal><ArticleTitle>Mexican position paper for the diagnosis and treatment of cardiac amyloidosis.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>33</EndPage><MedlinePgn>1-33</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.24875/ACM.M24000097</ELocationID><Abstract><AbstractText>La amiloidosis es una enfermedad heterog&#xe9;nea, de origen hereditario o adquirido, que se caracteriza por el dep&#xf3;sito anormal de prote&#xed;nas fibrilares en diversos tejidos. Esta enfermedad puede manifestarse de manera localizada o sist&#xe9;mica, lo que genera una amplia variabilidad en su presentaci&#xf3;n cl&#xed;nica y, frecuentemente, retrasa el diagn&#xf3;stico. Por ello, es fundamental la identificaci&#xf3;n temprana de los signos y s&#xed;ntomas para mejorar el pron&#xf3;stico. El primer posicionamiento mexicano sobre la amiloidosis card&#xed;aca tiene como objetivo resumir las principales caracter&#xed;sticas de la enfermedad y sus subtipos, identificando datos de alarma que incrementen la sospecha de su presencia. Adem&#xe1;s, busca ofrecer un algoritmo diagn&#xf3;stico que integre los estudios de imagen y de laboratorio disponibles en nuestro pa&#xed;s, con el fin de simplificar la toma de decisiones y llegar a un diagn&#xf3;stico de manera r&#xe1;pida, pr&#xe1;ctica y actualizada, basado en recomendaciones sustentadas en evidencia cient&#xed;fica. Una vez confirmado el diagn&#xf3;stico, se abordan los distintos retos terap&#xe9;uticos, tanto farmacol&#xf3;gicos como no farmacol&#xf3;gicos, ya que los pacientes no responden al tratamiento convencional de insuficiencia card&#xed;aca. Por ello, el tratamiento debe ser individualizado para cada paciente, teniendo en cuenta la presencia de otras comorbilidades. Finalmente, se presentan los principales factores pron&#xf3;sticos que guiar&#xe1;n un tratamiento adecuado, incluyendo los resultados del asesoramiento gen&#xe9;tico.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2024 Permanyer.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Berrios-B&#xe1;rcenas</LastName><ForeName>Enrique A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Cardiolog&#xed;a Ignacio Ch&#xe1;vez, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital Espa&#xf1;ol de M&#xe9;xico, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cigarroa-L&#xf3;pez</LastName><ForeName>Jos&#xe9; A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Hospital de Cardiolog&#xed;a Centro M&#xe9;dico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Asociaci&#xf3;n Mexicana de Insuficiencia Cardiaca, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Asociaci&#xf3;n Nacional de Cardi&#xf3;logos de M&#xe9;xico, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cossio-Aranda</LastName><ForeName>Jorge E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Sociedad Mexicana de Cardiolog&#xed;a, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>V&#xe1;squez-Ortiz</LastName><ForeName>Zuilma Y</ForeName><Initials>ZY</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Nutrici&#xf3;n Salvador Zubir&#xe1;n, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sociedad Nacional de Ecocardiograf&#xed;a de M&#xe9;xico, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro M&#xe9;dico ABC Santa Fe, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez-D&#xed;ez</LastName><ForeName>Gerardo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Centro M&#xe9;dico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sociedad Mexicana de Electrofisiolog&#xed;a y Estimulaci&#xf3;n Cardiaca, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baeza-Herrera</LastName><ForeName>Luis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Hospital Regional de Alta Especialidad de la Pen&#xed;nsula de Yucat&#xe1;n, Yucat&#xe1;n.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cordero-Cabra</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hospital Puerta de Hierro Norte, Jalisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morales-Portano</LastName><ForeName>Julieta</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centro M&#xe9;dico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alexanderson-Rosas</LastName><ForeName>Erick</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Cardiolog&#xed;a Ignacio Ch&#xe1;vez, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carvajal-Ju&#xe1;rez</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Cardiolog&#xed;a Ignacio Ch&#xe1;vez, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital de Cardiolog&#xed;a Centro M&#xe9;dico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xc1;lvarez-Sangabriel</LastName><ForeName>Amada</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Cardiolog&#xed;a Ignacio Ch&#xe1;vez, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jord&#xe1;n-R&#xed;os</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Cardiolog&#xed;a Ignacio Ch&#xe1;vez, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ivey-Miranda</LastName><ForeName>Juan B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Hospital de Cardiolog&#xed;a Centro M&#xe9;dico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Escalante-Seyffert</LastName><ForeName>Cecilia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Hospital Espa&#xf1;ol de M&#xe9;xico, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grimaldo</LastName><ForeName>Flavio A</ForeName><Initials>FA</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Cardiolog&#xed;a Ignacio Ch&#xe1;vez, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hern&#xe1;ndez-Reyes</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Nutrici&#xf3;n Salvador Zubir&#xe1;n, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>La&#xed;nez-Zelaya</LastName><ForeName>Jos&#xe9; S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Hospital Regional de Alta Especialidad Centenario de la Revoluci&#xf3;n Mexicana, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Morelos.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lara-Vargas</LastName><ForeName>Jorge A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Centro M&#xe9;dico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meave-Gonz&#xe1;lez</LastName><ForeName>Aloha</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Cardiolog&#xed;a Ignacio Ch&#xe1;vez, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ibarra-Ibarra</LastName><ForeName>Blanca R</ForeName><Initials>BR</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Cardiolog&#xed;a Ignacio Ch&#xe1;vez, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koretzky</LastName><ForeName>Solange G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Cardiolog&#xed;a Ignacio Ch&#xe1;vez, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital Infantil de M&#xe9;xico Federico G&#xf3;mez, Ciudad de M&#xe9;xico. M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maga&#xf1;a-Serrano</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Hospital de Cardiolog&#xed;a Centro M&#xe9;dico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Asociaci&#xf3;n Mexicana de Insuficiencia Cardiaca, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Asociaci&#xf3;n Nacional de Cardi&#xf3;logos de M&#xe9;xico, Ciudad de M&#xe9;xico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017065">Practice Guideline</PublicationType></PublicationTypeList><VernacularTitle>Posicionamiento mexicano para el diagn&#xf3;stico y tratamiento de amiloidosis cardiaca.</VernacularTitle></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Arch Cardiol Mex</MedlineTA><NlmUniqueID>101126728</NlmUniqueID><ISSNLinking>1665-1731</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="Y">Amyloidosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008800" MajorTopicYN="N" Type="Geographic">Mexico</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009202" MajorTopicYN="Y">Cardiomyopathies</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText>Amyloidosis is a heterogeneous, hereditary or acquired disease characterized by the abnormal deposition of fibrillar proteins in various tissues. The disease can be either localized or systemic, leading to significant variability in its clinical presentation and often causing diagnostic delays. For this reason, early identification of signs and symptoms is essential to improve prognosis. The first Mexican position paper on cardiac amyloidosis aims to summarize the main features of the disease and its subtypes, identifying warning signs that increase clinical suspicion. Additionally, it provides a diagnostic algorithm incorporating the imaging and laboratory studies available in our country, to streamline decision-making and facilitate a fast, practical, and up-to-date diagnosis based on evidence-based recommendations. Once the diagnosis is confirmed, the various therapeutic challenges of this disease, both pharmacological and non-pharmacological, are discussed, as patients do not respond to conventional heart failure treatments. Therefore, treatment must be individualized for each patient, considering the presence of other comorbidities. Finally, the key prognostic factors are outlined to guide appropriate treatment, including results from genetic counseling.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2024 Permanyer.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amiloidosis</Keyword><Keyword MajorTopicYN="N">Amiloidosis card&#xed;aca</Keyword><Keyword MajorTopicYN="N">Amiloidosis de inmunoglobulinas de cadenas ligeras</Keyword><Keyword MajorTopicYN="N">Amyloidosis</Keyword><Keyword MajorTopicYN="N">Cardiac amyloidosis</Keyword><Keyword MajorTopicYN="N">Diagnosis</Keyword><Keyword MajorTopicYN="N">Diagn&#xf3;stico</Keyword><Keyword MajorTopicYN="N">Prognosis. Treatment</Keyword><Keyword MajorTopicYN="N">Pron&#xf3;stico. Tratamiento</Keyword><Keyword MajorTopicYN="N">Transthyretin</Keyword><Keyword MajorTopicYN="N">Transtiretina</Keyword><Keyword MajorTopicYN="N">inmunoglobulin light-chain amyloidosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>30</Day><Hour>18</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>30</Day><Hour>18</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>30</Day><Hour>17</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39476401</ArticleId><ArticleId IdType="pmc">PMC12169347</ArticleId><ArticleId IdType="doi">10.24875/ACM.M24000097</ArticleId><ArticleId IdType="pii">j94/Supl 3/1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation. 2017;135(14):1357&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5392416</ArticleId><ArticleId IdType="pubmed">28373528</ArticleId></ArticleIdList></Reference><Reference><Citation>Correction to:Cardiac amyloidosis:Evolving diagnosis and management:A scientific statement from the American Heart Association. Circulation. 2021;144(1):e11.</Citation><ArticleIdList><ArticleId IdType="pubmed">34228483</ArticleId></ArticleIdList></Reference><Reference><Citation>Gertz MA, Dispenzieri A, Sher T. Pathophysiology and treatment of cardiac amyloidosis. Nat Rev Cardiol. 2015;12(2):91&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">25311231</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqi OK, Ruberg FL. Cardiac amyloidosis:An update on pathophysiology, diagnosis, and treatment. Trends Cardiovasc Med. 2018;28((1)):10&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5741539</ArticleId><ArticleId IdType="pubmed">28739313</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018;379((11)):1007&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">30145929</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyle RA, Larson DR, Kurtin PJ, Kumar S, Cerhan JR, Therneau TM, et al. Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015. Mayo Clin Proc. 2019;94(3):465&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6401262</ArticleId><ArticleId IdType="pubmed">30713046</ArticleId></ArticleIdList></Reference><Reference><Citation>Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349(6):583&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">12904524</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Naharro A, Hawkins PN, Fontana M. Cardiac amyloidosis. Clin Med (Lond) 2018;18((Suppl 2)):s30&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6334035</ArticleId><ArticleId IdType="pubmed">29700090</ArticleId></ArticleIdList></Reference><Reference><Citation>Montserrat Moliner A, Waligora J. The European Union policy in the field of rare diseases. Adv Exp Med Biol. 2017;1031:561&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">29214592</ArticleId></ArticleIdList></Reference><Reference><Citation>Aimo A, Merlo M, Porcari A, Georgiopoulos G, Pagura L, Vergaro G, et al. Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies. Eur J Heart Fail. 2022;24(12):2342&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10084346</ArticleId><ArticleId IdType="pubmed">35509173</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravichandran S, Lachmann HJ, Wechalekar AD. Epidemiologic and survival trends in amyloidosis, 1987-2019. N Engl J Med. 2020;382((16)):1564&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">32294353</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz MW, Barroso F, Gonz&#xe1;lez-Duarte A, Mundayat R, Ong ML. The demographic, genetic, and clinical characteristics of Latin American subjects enrolled in the Transthyretin Amyloidosis Outcomes Survey. Amyloid. 2017;24:107&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">28434322</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez-Duarte A, C&#xe1;rdenas-Soto K, Ba&#xf1;uelos CE, Fueyo O, Dominguez C, Torres B, et al. Amyloidosis due to TTR mutations in Mexico with 4 distincts genotypes in the index cases. Orphanet J Rare Dis. 2018;13(1):107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6029070</ArticleId><ArticleId IdType="pubmed">29970125</ArticleId></ArticleIdList></Reference><Reference><Citation>Arshad S, Goldberg YH, Bhopalwala H, Dewaswala N, Miceli NS, Birks EJ, et al. High prevalence of cardiac amyloidosis in clinically significant aortic stenosis:a meta-analysis. Cardiol Res. 2022;13(6):357&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9822671</ArticleId><ArticleId IdType="pubmed">36660066</ArticleId></ArticleIdList></Reference><Reference><Citation>Magdi M, Mostafa MR, Abusnina W, Al-abdouh A, Doss R, Mohamed S, et al. A systematic review and meta-analysis of the prevalence of transthyretin amyloidosis in heart failure with preserved ejection fraction. Am J Cardiovasc Dis. 2022;12(3):102&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9301026</ArticleId><ArticleId IdType="pubmed">35873185</ArticleId></ArticleIdList></Reference><Reference><Citation>Nils FK, Ana F, Mahmoud G, Mark H, Rozenbaum H. Estimating the gender distribution of patients with wild-type transthyretin amyloid cardiomyopathy:a systematic review and meta-analysis. Cardiol Ther. 2021;10(1):41&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8126539</ArticleId><ArticleId IdType="pubmed">33315233</ArticleId></ArticleIdList></Reference><Reference><Citation>Nativi-Nicolau J, Siu A, Dispenzieri A, Maurer MS, Rapezzi C, Kristen AV, et al. Temporal trends of wild-type transthyretin amyloid cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey. JACC CardioOncol. 2021;3(4):537&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8543133</ArticleId><ArticleId IdType="pubmed">34729526</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinney JH, Whelan CJ, Petrie A, Dungu J, Banypersad SM, Sattianayagam P, et al. Senile systemic amyloidosis:clinical features at presentation and outcome. J Am Heart Assoc. 2013;2(2):e000098.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3647259</ArticleId><ArticleId IdType="pubmed">23608605</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013;121(17):3420&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">23479568</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaxman I, Gertz M. When to suspect a diagnosis of amyloidosis. Acta Haematol. 2020;143(4):304&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">32340017</ArticleId></ArticleIdList></Reference><Reference><Citation>Papa R, Lachmann HJ. Secondary, AA, amyloidosis. Rheum Dis Clin North Am. 2018;44(4):585&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pubmed">30274625</ArticleId></ArticleIdList></Reference><Reference><Citation>Lachmann HJ, Goodman HJB, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356(23):2361&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">17554117</ArticleId></ArticleIdList></Reference><Reference><Citation>Sattianayagam PT, Hawkins PN, Gillmore JD. Systemic amyloidosis and the gastrointestinal tract. Nat Rev Gastroenterol Hepatol. 2009;6(10):608&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">19724253</ArticleId></ArticleIdList></Reference><Reference><Citation>Fotiou D, Dimopoulos MA, Kastritis E. Systemic AL amyloidosis:current approaches to diagnosis and management. Hemasphere. 2020;4(4):12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7430233</ArticleId><ArticleId IdType="pubmed">32885146</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwa YL, Fogaren T, Sams A, Faller DV, Stull DM, Thuenemann S, et al. Immunoglobulin light-chain amyloidosis:clinical presentations and diagnostic approach. J Adv Pract Oncol. 2019;10(5):470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7779572</ArticleId><ArticleId IdType="pubmed">33457060</ArticleId></ArticleIdList></Reference><Reference><Citation>Bird J. Guidelines on the diagnosis and management of AL amyloidosis. Br J Haematol. 2004;125(6):681&#x2013;700.</Citation><ArticleIdList><ArticleId IdType="pubmed">15180858</ArticleId></ArticleIdList></Reference><Reference><Citation>Merlini G, Palladini G. Differential diagnosis of monoclonal gammopathy of undetermined significance. Hematology Am Soc Hematol Educ Program. 2012;2012:595&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pubmed">23233640</ArticleId></ArticleIdList></Reference><Reference><Citation>Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RK, Clarke JO, et al. 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis:A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023;81(11):1076&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">36697326</ArticleId></ArticleIdList></Reference><Reference><Citation>Nativi-Nicolau JN, Karam C, Khella S, Maurer MS. Screening for ATTR amyloidosis in the clinic:overlapping disorders, misdiagnosis, and multiorgan awareness. Heart Fail Rev. 2022;27(3):785&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9033715</ArticleId><ArticleId IdType="pubmed">33609196</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau:A population-based autopsy study. Ann Med. 2008;40(3):232&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">18382889</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperry BW, Reyes BA, Ikram A, Donnelly JP, Phelan D, Jaber WA, et al. Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release. J Am Coll Cardiol. 2018;72(17):2040&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">30336828</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez-L&#xf3;pez E, Gallego-Delgado M, Guzzo-Merello G, De Haro-Del Moral FJ, Cobo-Marcos M, Robles C, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">26224076</ArticleId></ArticleIdList></Reference><Reference><Citation>Treibel TA, Fontana M, Gilbertson JA, Castelletti S, White SK, Scully PR, et al. Occult transthyretin cardiac amyloid in severe calcific aortic stenosis. Circ Cardiovasc Imaging. 2016;9(8):e005066.</Citation><ArticleIdList><ArticleId IdType="pubmed">27511979</ArticleId></ArticleIdList></Reference><Reference><Citation>Castan&#xf5; A, Bokhari S, Maurer MS. Unveiling wild-type transthyretin cardiac amyloidosis as a significant and potentially modifiable cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2595&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">26224073</ArticleId></ArticleIdList></Reference><Reference><Citation>Eldhagen P, Berg S, Lund LH, S&#xf6;rensson P, Suhr OB, Westermark P. Transthyretin amyloid deposits in lumbar spinal stenosis and assessment of signs of systemic amyloidosis. J Intern Med. 2021;289(6):895&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8248398</ArticleId><ArticleId IdType="pubmed">33274477</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapezzi C, Elliott P, Damy T, Nativi-Nicolau J, Berk JL, Velazquez EJ, et al. Efficacy of tafamidis in patients with hereditary and wild-type transthyretin amyloid cardiomyopathy:further analyses from ATTR-ACT. JACC Heart Fail. 2021;9(2):115&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">33309574</ArticleId></ArticleIdList></Reference><Reference><Citation>Murtagh B, Hammill SC, Gertz MA, Kyle RA, Tajik AJ, Grogan M. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol. 2005;95(4):535&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15695149</ArticleId></ArticleIdList></Reference><Reference><Citation>Cyrille NB, Goldsmith J, Alvarez J, Maurer MS. Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis. Am J Cardiol. 2014;114(7):1089&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">25212550</ArticleId></ArticleIdList></Reference><Reference><Citation>Abstract 16852:A Simple Voltage/Mass Index Improves Diagnosis of Cardiac Amyloidosis in Patients With Unexplained Left Ventricular &#x201c;Hypertrophy&#x201d;:An Electrocardiographic and Echocardiographic Study of More Than 500 Patients. Circulation [Internet] 2010;122((Suppl. 21)) [cited 2024 Aug 22] Disponible en: https://www.ahajournals.org/doi/10.1161/circ.122.suppl_21. A16852 .</Citation></Reference><Reference><Citation>Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, et al. Systemic cardiac amyloidoses:Disease profiles and clinical courses of the 3 main types. Circulation. 2009;120(13):1203&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">19752327</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Z, Kang L, Tian Z, Chen W, Guo W, Xu J, et al. Utility of combined indexes of electrocardiography and echocardiography in the diagnosis of biopsy proven primary cardiac amyloidosis. Ann Noninvasive Electrocardiol. 2011;16(1):25&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6932607</ArticleId><ArticleId IdType="pubmed">21251130</ArticleId></ArticleIdList></Reference><Reference><Citation>Yilmaz A, Bauersachs J, Bengel F, B&#xfc;chel R, Kindermann I, Klingel K, et al. Diagnosis and treatment of cardiac amyloidosis:position statement of the German Cardiac Society (DGK) Clin Res Cardiol. 2021;110((4)):479&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055575</ArticleId><ArticleId IdType="pubmed">33459839</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperry BW, Vranian MN, Hachamovitch R, Joshi H, McCarthy M, Ikram A, et al. Are classic predictors of voltage valid in cardiac amyloidosis?A contemporary analysis of electrocardiographic findings. Int J Cardiol. 2016;214:477&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">27093686</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappelli F, Vignini E, Martone R, Perlini S, Mussinelli R, Sabena A, et al. Baseline ECG features and arrhythmic profile in transthyretin versus light chain cardiac amyloidosis. Circ Heart Fail. 2020;13(3):E006619.</Citation><ArticleIdList><ArticleId IdType="pubmed">32164434</ArticleId></ArticleIdList></Reference><Reference><Citation>Cipriani A, De Michieli L, Porcari A, Licchelli L, Sinigiani G, Tini G, et al. Low QRS voltages in cardiac amyloidosis:clinical correlates and prognostic value. JACC CardioOncol. 2022;4(4):458&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9700257</ArticleId><ArticleId IdType="pubmed">36444225</ArticleId></ArticleIdList></Reference><Reference><Citation>Mussinelli R, Salinaro F, Alogna A, Boldrini M, Raimondi A, Musca F, et al. Diagnostic and prognostic value of low QRS voltages in cardiac AL amyloidosis. Ann Noninvasive Electrocardiol. 2013;18(3):271&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6932192</ArticleId><ArticleId IdType="pubmed">23714086</ArticleId></ArticleIdList></Reference><Reference><Citation>Kristen AV, Perz JB, Schonland SO, Hegenbart U, Schnabel PA, Kristen JH, et al. Non-invasive predictors of survival in cardiac amyloidosis. Eur J Heart Fail. 2007;9((6-7)):617&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">17350331</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson P, Karp K, Bjerle P, Olofsson BO. Disturbances of cardiac rhythm and conduction in familial amyloidosis with polyneuropathy. Heart. 1984;51(6):658&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC481569</ArticleId><ArticleId IdType="pubmed">6329251</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez-L&#xf3;pez E, Gagliardi C, Dominguez F, Quarta CC, De Haro-Del Moral FJ, Milandri A, et al. Clinical characteristics of wild-type transthyretin cardiac amyloidosis:disproving myths. Eur Heart J. 2017;38((24)):1895&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pubmed">28329248</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartnett J, Jaber W, Maurer M, Sperry B, Hanna M, Collier P, et al. Electrophysiological manifestations of cardiac amyloidosis:JACC:CardioOncology State-of-the-Art Review. JACC CardioOncol. 2021;3(4):506&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8543134</ArticleId><ArticleId IdType="pubmed">34729522</ArticleId></ArticleIdList></Reference><Reference><Citation>Reisinger J, Dubrey SW, Lavalley M, Skinner M, Falk RH. Electrophysiologic abnormalities in AL (primary) amyloidosis with cardiac involvement. J Am Coll Cardiol. 1997;30(4):1046&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">9316537</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubrey SW, Cha K, Anderson J, Chamarthi B, Reisinger J, Skinner M, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM. 1998;91(2):141&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">9578896</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldsmith YB, Liu J, Chou J, Hoffman J, Comenzo RL, Steingart RM. Frequencies and types of arrhythmias in patients with systemic light-chain amyloidosis with cardiac involvement undergoing stem cell transplantation on telemetry monitoring. Am J Cardiol. 2009;104(7):990&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">19766769</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma S, Labib SB, Shah SP. Electrocardiogram criteria to diagnose cardiac amyloidosis in men with a bundle branch block. Am J Cardiol. 2021;146:89&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">33529617</ArticleId></ArticleIdList></Reference><Reference><Citation>Alreshq R, Tugal D, Siddiqi O, Ruberg F. Conduction abnormalities and role of cardiac pacing in cardiac amyloidosis:A systematic review. Pacing Clin Electrophysiol. 2021;44(12):2092&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">34632598</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbhaiya CR, Kumar S, Baldinger SH, Michaud GF, Stevenson WG, Falk R, et al. Electrophysiologic assessment of conduction abnormalities and atrial arrhythmias associated with amyloid cardiomyopathy. Heart Rhythm. 2016;13(2):383&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">26400855</ArticleId></ArticleIdList></Reference><Reference><Citation>Namdar M, Steffel J, Jetzer S, Schmied C, Hrlimann D, Camici GG, et al. Value of electrocardiogram in the differentiation of hypertensive heart disease, hypertrophic cardiomyopathy, aortic stenosis, amyloidosis, and fabry disease. Am J Cardiol. 2012;109(4):587&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">22105784</ArticleId></ArticleIdList></Reference><Reference><Citation>Banypersad SM, Fontana M, Maestrini V, Sado DM, Captur G, Petrie A, et al. T1 mapping and survival in systemic light-chain amyloidosis. Eur Heart J. 2015;36(4):244&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4301598</ArticleId><ArticleId IdType="pubmed">25411195</ArticleId></ArticleIdList></Reference><Reference><Citation>Phelan D, Collier P, Thavendiranathan P, Popovi&#x107; ZB, Hanna M, Plana JC, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart. 2012;98(19):1442&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">22865865</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SP, Park JB, Kim HK, Kim YJ, Grogan M, Sohn DW. Contemporary imaging diagnosis of cardiac amyloidosis. J Cardiovasc Imaging. 2019;27(1):1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6358430</ArticleId><ArticleId IdType="pubmed">30701710</ArticleId></ArticleIdList></Reference><Reference><Citation>Roger-Roll&#xe9; A, Cariou E, Rguez K, Fournier P, Lavie-Badie Y, Blanchard V, et al. Can myocardial work indices contribute to the exploration of patients with cardiac amyloidosis? Open Heart. 2020;7(2):e001346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7555098</ArticleId><ArticleId IdType="pubmed">33051335</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmiero G, Rubino M, Monda E, Caiazza M, D'urso L, Carlomagno G, et al. Global left ventricular myocardial work efficiency in heart failure patients with cardiac amyloidosis:pathophysiological implications and role in differential diagnosis. J Cardiovasc Echogr. 2021;31((3)):157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8603776</ArticleId><ArticleId IdType="pubmed">34900551</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert consensus recommendations for multimodality imaging in cardiac amyloidosis:Part 1 of 2 - Evidence base and standardized methods of imaging. Circ Cardiovasc Imaging. 2021;14(7):e000029.</Citation><ArticleIdList><ArticleId IdType="pubmed">34196223</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L, Tian Z, Fang Q. Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis:A systematic review and meta-analysis. BMC Cardiovasc Disord. 2016;16(1):1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4897958</ArticleId><ArticleId IdType="pubmed">27267362</ArticleId></ArticleIdList></Reference><Reference><Citation>Syed IS, Glockner JF, Feng DL, Araoz PA, Martinez MW, Edwards WD, et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging. 2010;3(2):155&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">20159642</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalho FP de, Erthal F, Azevedo CF. The role of cardiac MR imaging in the assessment of patients with cardiac amyloidosis. Magn Reson Imaging Clin N Am. 2019;27(3):453&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">31279449</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaguchi S, Oda S, Kidoh M, Hayashi H, Takashio S, Usuku H, et al. Cardiac MRI T1 and T2 mapping as a quantitative imaging biomarker in transthyretin amyloid cardiomyopathy. Acad Radiol. 2024;31(2):514&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">37775448</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Naharro A, Treibel TA, Abdel-Gadir A, Bulluck H, Zumbo G, Knight DS, et al. Magnetic resonance in transthyretin cardiac amyloidosis. J Am Coll Cardiol. 2017;70(4):466&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">28728692</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis:Part 2 of 2&#x2013;Evidence base and standardized methods of imaging. J Nuclear Cardiol. 2019;26(6):2065&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">31468376</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis:Part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol. 2021;28(4):1769&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">34196911</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurer MS, Bokhari S, Damy T, Dorbala S, Drachman BM, Fontana M, et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ Heart Fail. 2019;12((9)):e006075.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6736650</ArticleId><ArticleId IdType="pubmed">31480867</ArticleId></ArticleIdList></Reference><Reference><Citation>Waheed A, Dorbala S. Current status of radionuclide imaging of transthyretin cardiac amyloidosis. Cardiol Clin. 2023;41(2):217&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11140431</ArticleId><ArticleId IdType="pubmed">37003679</ArticleId></ArticleIdList></Reference><Reference><Citation>Meristoudis G, Ilias I, Keramida G. Potential diagnostic pitfalls of bone scintigraphy in transthyretin-related amyloidosis. World J Nucl Med. 2020;19(03):313&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745849</ArticleId><ArticleId IdType="pubmed">33354195</ArticleId></ArticleIdList></Reference><Reference><Citation>Saad JM, Ahmed AI, Han Y, Saeed S, Pournazari P, Al-Mallah MH. 99mTechnetium-labeled cardiac scintigraphy for suspected amyloidosis:a review of current and future directions. Heart Fail Rev. 2022;27(5):1493&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">34709500</ArticleId></ArticleIdList></Reference><Reference><Citation>Embry-Dierson M, Farrell MB, Schockling E, Warren J, Jerome S. Cardiac amyloidosis imaging, Part 1:amyloidosis etiology and image acquisition. J Nucl Med Technol. 2023;51(2):83&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">37268319</ArticleId></ArticleIdList></Reference><Reference><Citation>Schockling EJ, Farrell MB, Embry-Dierson M, Warren J, Jerome S. Cardiac amyloidosis imaging, Part 2:quantification and technical considerations. J Nucl Med Technol. 2023;51(2):90&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">37268318</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorbala S, Cuddy S, Falk RH. How to image cardiac amyloidosis:a practical approach. JACC Cardiovasc Imaging. 2020;13(6):1368&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7148180</ArticleId><ArticleId IdType="pubmed">31607664</ArticleId></ArticleIdList></Reference><Reference><Citation>Jerome S, Farrell MB, Warren J, Embry-Dierson M, Schockling EJ. Cardiac amyloidosis imaging, Part 3:interpretation, diagnosis, and treatment. J Nucl Med Technol. 2023;51(2):102&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">37268322</ArticleId></ArticleIdList></Reference><Reference><Citation>Joseph V, Julien HM, Bravo PE. Radionuclide imaging of cardiac amyloidosis. PET Clin. 2021;16(2):285&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">33589384</ArticleId></ArticleIdList></Reference><Reference><Citation>Khor YM, Cuddy SAM, Singh V, Falk RH, Di Carli MF, Dorbala S. 99mTc bone-avid tracer cardiac scintigraphy:role in noninvasive diagnosis of transthyretin cardiac amiloidosis. Radiology. 2023;306(2):e221082.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9885342</ArticleId><ArticleId IdType="pubmed">36537896</ArticleId></ArticleIdList></Reference><Reference><Citation>Poterucha TJ, Elias P, Bokhari S, Einstein AJ, DeLuca A, Kinkhabwala M, et al. Diagnosing transthyretin cardiac amyloidosis by technetium Tc 99m pyrophosphate:a test in evolution. JACC Cardiovasc Imaging. 2021;14(6):1221&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8113330</ArticleId><ArticleId IdType="pubmed">33221204</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis:A position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021;42(16):1554&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8060056</ArticleId><ArticleId IdType="pubmed">33825853</ArticleId></ArticleIdList></Reference><Reference><Citation>Brito D, Albrecht FC, De Arenaza DP, Bart N, Better N, Carvajal-Juarez I, et al. World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) Glob Heart. 2023;18(1):59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10607607</ArticleId><ArticleId IdType="pubmed">37901600</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">27143678</ArticleId></ArticleIdList></Reference><Reference><Citation>Witteles RM, Bokhari S, Damy T, Elliott PM, Falk RH, Fine NM, et al. Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice. JACC Heart Fail. 2019;7(8):709&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">31302046</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang CC, Chang WT, Lin YH, Tzeng BH, Chao TH, Hung CL, et al. 2023 Expert Consensus of the Taiwan Society of Cardiology on the Diagnosis and Treatment of Cardiac Amyloidosis. Acta Cardiol Sin. 2023;39(4):511&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10346051</ArticleId><ArticleId IdType="pubmed">37456934</ArticleId></ArticleIdList></Reference><Reference><Citation>Papathanasiou M, Carpinteiro A, Rischpler C, Hagenacker T, Rassaf T, Luedike P. Diagnosing cardiac amyloidosis in every-day practice:A practical guide for the cardiologist. Int J Cardiol Heart Vasc. 2020;28:100519.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7191222</ArticleId><ArticleId IdType="pubmed">32373710</ArticleId></ArticleIdList></Reference><Reference><Citation>Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure:a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023;118(17):3272&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">35150240</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Hueso R, Salamanca-Bautista P, Quesada-Sim&#xf3;n MA, Yun S, Conde-Martel A, Morales-Rull JL, et al. Estimating the prevalence of cardiac amyloidosis in old patients with heart failure&#x2013;barriers and opportunities for improvement:the PREVAMIC study. J Clin Med. 2023;12((6))</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10057876</ArticleId><ArticleId IdType="pubmed">36983274</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilstrap LG, Dominici F, Wang Y, El-Sady MS, Singh A, Di Carli MF, et al. Epidemiology of cardiac amyloidosis-associated heart failure hospitalizations among fee-for-service medicare beneficiaries in the United States. Circ Heart Fail. 2019;12(6):2273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6557425</ArticleId><ArticleId IdType="pubmed">31170802</ArticleId></ArticleIdList></Reference><Reference><Citation>Banypersad SM, Moon JC, Whelan C, Hawkins PN, Wechalekar AD. Updates in cardiac amyloidosis:A review. J Am Heart Assoc. 2012;1((2)):e000364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3487372</ArticleId><ArticleId IdType="pubmed">23130126</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin JM, Maurer MS. Transthyretin cardiac amyloidosis:A treatable form of heart failure with a preserved ejection fraction. Trends Cardiovasc Med. 2021;31(1):59&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7297649</ArticleId><ArticleId IdType="pubmed">31889610</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobner S, Bernhard B, Asatryan B, Windecker S, Stortecky S, Pilgrim T, et al. SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy:early tolerance and clinical response to dapagliflozin. ESC Heart Fail. 2023;10(1):397&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9871707</ArticleId><ArticleId IdType="pubmed">36259276</ArticleId></ArticleIdList></Reference><Reference><Citation>Porcari A, Cappelli F, Nitsche C, Tomasoni D, Sinigiani G, Longhi S, et al. SGLT2 inhibitor therapy in patients with transthyretin amyloid cardiomyopathy. J Am Coll Cardiol. 2024;83(24):2411&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">38866445</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly JP, Hanna M. Cardiac amyloidosis:An update on diagnosis and treatment. Cleve Clin J Med. 2017;84:12&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">29257735</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin JM, Rosenthal JL, Grodin JL, Maurer MS, Grogan M, Cheng RK. ATTR amyloidosis:Current and emerging management strategies. JACC CardioOncol. 2021;3(4):488&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8543085</ArticleId><ArticleId IdType="pubmed">34729521</ArticleId></ArticleIdList></Reference><Reference><Citation>Giancaterino S, Urey MA, Darden D, Hsu JC. Management of arrhythmias in cardiac amyloidosis. JACC Clin Electrophysiol. 2020;6(4):351&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">32327068</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng DL, Syed IS, Martinez M, Oh JK, Jaffe AS, Grogan M, et al. Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis. Circulation. 2009;119(18):2490&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">19414641</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubrey S, Pollak A, Skinner M, Falk RH, Falk RH. Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis:evidence for atrial electromechanical dissociation. Br Heart J. 1995;74(5):541&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC484078</ArticleId><ArticleId IdType="pubmed">8562243</ArticleId></ArticleIdList></Reference><Reference><Citation>Bukhari Syed, Khan Sz, Bashir Z. Atrial fibrillation, thromboembolic risk, and anticoagulation in cardiac amyloidosis:a review. J Card Fail. 2023;29(1):76&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">36122817</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnellan E, Wazni O, Kanj M, Elshazly MB, Hussein A, Baranowski B, et al. Atrial fibrillation ablation in patients with transthyretin cardiac amyloidosis. Europace. 2020;22(2):259&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">32031230</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilches S, Fontana M, Gonzalez-Lopez E, Mitrani L, Saturi G, Renju M, et al. Systemic embolism in amyloid transthyretin cardiomyopathy. Eur J Heart Fail. 2022;24(8):1387&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9542906</ArticleId><ArticleId IdType="pubmed">35650018</ArticleId></ArticleIdList></Reference><Reference><Citation>Bukhari S, Barakat AF, Eisele YS, Nieves R, Jain S, Saba S, et al. Prevalence of atrial fibrillation and thromboembolic risk in wild-type transthyretin amyloid cardiomyopathy. Circulation. 2021;143(13):1335&#x2013;1337.</Citation><ArticleIdList><ArticleId IdType="pubmed">33779268</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappelli F, Tini G, Russo D, Emdin M, Del Franco A, Vergaro G, et al. Arterial thrombo-embolic events in cardiac amyloidosis:a look beyond atrial fibrillation. Amyloid. 2021;28(1):12&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">32981389</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure:A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895&#x2013;e1032.</Citation><ArticleIdList><ArticleId IdType="pubmed">35363499</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitrani LR, De Los Santos J, Driggin E, Kogan R, Helmke S, Goldsmith J, et al. Anticoagulation with warfarin compared to novel oral anticoagulants for atrial fibrillation in adults with transthyretin cardiac amyloidosis:comparison of thromboembolic events and major bleeding. Amyloid. 2021;28(1):30&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8018530</ArticleId><ArticleId IdType="pubmed">32814468</ArticleId></ArticleIdList></Reference><Reference><Citation>Laptseva N, Rossi VA, Sudano I, Schwotzer R, Ruschitzka F, Flammer AJ, et al. Arrhythmic manifestations of cardiac amyloidosis:challenges in risk stratification and clinical management. J Clin Med. 2023;2581;12(7)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10095126</ArticleId><ArticleId IdType="pubmed">37048664</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim EJ, Holmes BB, Huang S, Lugo R, Aboud A Al, Goodman S, et al. Outcomes in patients with cardiac amyloidosis and implantable cardioverter-defibrillator. Europace. 2020;22(8):1216&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">32514579</ArticleId></ArticleIdList></Reference><Reference><Citation>John R. Arrhythmias in cardiac amyloidosis. J Innov Card Rhythm Manag. 2018;9(3):3051&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7252761</ArticleId><ArticleId IdType="pubmed">32477799</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death:Executive Summary. Circulation. 2018;138(13):e210&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">29084733</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Arbelo E, Barriales-Villa R, et al. 2023 ESC Guidelines for the management of cardiomyopathies:Developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC) Eur Heart J. 2023;44(37):3503&#x2013;626.</Citation><ArticleIdList><ArticleId IdType="pubmed">37622657</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeppenfeld K, Tfelt-Hansen J, De Riva M, Winkel BG, Behr ER, Blom NA, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43(40):3997&#x2013;4126.</Citation><ArticleIdList><ArticleId IdType="pubmed">36017572</ArticleId></ArticleIdList></Reference><Reference><Citation>Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Europace. 2022;24(1):71&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">34455427</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung CC, Roston TM, Andrade JG, Bennett MT, Davis MK. Arrhythmias in cardiac amyloidosis:challenges in risk stratification and treatment. Can J Cardiol. 2020;36(3):416&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">32145868</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurer MS, Kale P, Fontana M, Berk JL, Grogan M, Gustafsson F, et al. Patisiran treatment in patients with transthyretin cardiac amyloidosis. N Engl J Med. 2023;389(17):1553&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10757426</ArticleId><ArticleId IdType="pubmed">37888916</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqi OK, Mints YY, Berk JL, Connors L, Doros G, Gopal DM, et al. Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy:the Boston University Amyloidosis Center experience. Amyloid. 2022;29(2):71&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9258521</ArticleId><ArticleId IdType="pubmed">35083944</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">30145929</ArticleId></ArticleIdList></Reference><Reference><Citation>Damy T, Garcia-Pavia P, Hanna M, Judge DP, Merlini G, Gundapaneni B, et al. Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. Eur J Heart Fail. 2021;23(2):277&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8048553</ArticleId><ArticleId IdType="pubmed">33070419</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillmore JD, Judge DP, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs S, et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med. 2024;390(2):132&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">38197816</ArticleId></ArticleIdList></Reference><Reference><Citation>Karlstedt E, Jimenez-Zepeda V, Howlett JG, White JA, Fine NM. Clinical experience with the use of doxycycline and ursodeoxycholic acid for the treatment of transthyretin cardiac amyloidosis. J Card Fail. 2019;25(3):147&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">30660664</ArticleId></ArticleIdList></Reference><Reference><Citation>aus dem Siepen F, Bauer R, Aurich M, Buss SJ, Steen H, Altland K, et al. Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis:an observational study. Drug Des Devel Ther. 2015;9:6319&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4675646</ArticleId><ArticleId IdType="pubmed">26673202</ArticleId></ArticleIdList></Reference><Reference><Citation>Macedo AVS, Schwartzmann PV, de Gusm&#xe3;o BM, de Melo MDT, Coelho-Filho OR. Advances in the treatment of cardiac amyloidosis. Curr Treat Options Oncol. 2020;21(5):36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7181421</ArticleId><ArticleId IdType="pubmed">32328845</ArticleId></ArticleIdList></Reference><Reference><Citation>Milani P, Merlini G, Palladini G. Light chain amyloidosis. Mediterr J Hematol Infect Dis. 2018;10(1):e2018022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5841939</ArticleId><ArticleId IdType="pubmed">29531659</ArticleId></ArticleIdList></Reference><Reference><Citation>Palladini G, Sch&#xf6;nland S, Merlini G, Milani P, Jaccard A, Bridoux F, et al. The management of light chain (AL) amyloidosis in Europe:clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018. Blood Cancer J. 2023;13(1):19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9876983</ArticleId><ArticleId IdType="pubmed">36697388</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung N, Bridoux F, Nasr SH. Monoclonal gammopathy of renal significance. N Engl J Med. 2021;384(20):1931&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">34010532</ArticleId></ArticleIdList></Reference><Reference><Citation>Oe Y, Soma J, Sato H, Ito S. Heavy chain deposition disease:An overview. Clin Exp Nephrol. 2013;17(6):771&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">23652830</ArticleId></ArticleIdList></Reference><Reference><Citation>Ihne S, Morbach C, Obici L, Palladini G, St&#xf6;rk S. Amyloidosis in heart failure. Curr Heart Fail Rep. 2019;16(6):285&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">31782077</ArticleId></ArticleIdList></Reference><Reference><Citation>Palladini G, Russo P, Bosoni T, Verga L, Sarais G, Lavatelli F, et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem. 2009;55(3):499&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pubmed">19131635</ArticleId></ArticleIdList></Reference><Reference><Citation>Madan S, Dispenzieri A, Lacy MQ, Buadi F, Hayman SR, Zeldenrust SR, et al. Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma. Mayo Clin Proc. 2010;85(3):232&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2843113</ArticleId><ArticleId IdType="pubmed">20194151</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajkumar SV, Gertz MA, Kyle RA. Primary systemic amyloidosis with delayed progression to multiple myeloma. Cancer. 1998;82(8):1501&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">9554527</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajkumar SV. Multiple myeloma:2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91(7):719&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5291298</ArticleId><ArticleId IdType="pubmed">27291302</ArticleId></ArticleIdList></Reference><Reference><Citation>Eder L, Bitterman H. Images in clinical medicine Amyloid Purpura. N Engl J Med. 2007;2406;356(23)</Citation><ArticleIdList><ArticleId IdType="pubmed">17554122</ArticleId></ArticleIdList></Reference><Reference><Citation>Mumford AD, O'Donnell J, Gillmore JD, Manning RA, Hawkins PN, Laffan M. Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis. Br J Haematol. 2000;110(2):454&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">10971408</ArticleId></ArticleIdList></Reference><Reference><Citation>Bochtler T, Hegenbart U, Kunz C, Granzow M, Benner A, Seckinger A, et al. Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens. J Clin Oncol. 2015;33(12):1371&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">25779559</ArticleId></ArticleIdList></Reference><Reference><Citation>Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, et al. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med. 2021;385(1):46&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">34192431</ArticleId></ArticleIdList></Reference><Reference><Citation>Merlini G, Dispenzieri A, Sanchorawala V, Sch&#xf6;nland SO, Palladini G, Hawkins PN, et al. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018;4(1):38.</Citation><ArticleIdList><ArticleId IdType="pubmed">30361521</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhutani D, Lentzsch S. Diagnosis and management of systemic light chain AL amyloidosis. Pharmacol Ther. 2020;214:107612.</Citation><ArticleIdList><ArticleId IdType="pubmed">32562825</ArticleId></ArticleIdList></Reference><Reference><Citation>Manwani R, Cohen O, Sharpley F, Mahmood S, Sachchithanantham S, Foard D, et al. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood. 2019;134(25):2271&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">31578202</ArticleId></ArticleIdList></Reference><Reference><Citation>Decotto S, Villanueva E, de Arenaza P&#xe9;rez D, Nucifora EM, Aguirre MA, Posadas-Mart&#xed;nez ML, et al. Heart transplantation in amyloidosis. Clinical and imaging manifestations. Arch Cardiol Mex. 2022;92(3):320&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9262297</ArticleId><ArticleId IdType="pubmed">34619747</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, Baran DA, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation:A 10-year update. J Heart Lung Transplant. 2016;35(1):1&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">26776864</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsich E, Singh TP, Cherikh WS, Harhay MO, Hayes D, Perch M, et al. The International thoracic organ transplant registry of the international society for heart and lung transplantation:Thirty-ninth adult heart transplantation report&#x2013;2022;focus on transplant for restrictive heart disease. J Heart Lung Transplant. 2022;41(10):1366&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10281817</ArticleId><ArticleId IdType="pubmed">36031520</ArticleId></ArticleIdList></Reference><Reference><Citation>Sousa M, Monohan G, Rajagopalan N, Grigorian A, Guglin M. Heart transplantation in cardiac amyloidosis. Vol. 22, Heart Failure Reviews. Springer New York LLC. 2017:317&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">28281017</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis MK, Kale P, Liedtke M, Schrier S, Arai S, Wheeler M, et al. Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era. Am J Transplant. 2015;15(3):650&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">25648766</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilas-Boas M do C, Rocha AP, Cardoso MN, Fernandes JM, Coelho T, Cunha JPS. Clinical 3-D gait assessment of patients with polyneuropathy associated with hereditary transthyretin amyloidosis. Front Neurol. 2020;11:605282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7719818</ArticleId><ArticleId IdType="pubmed">33329366</ArticleId></ArticleIdList></Reference><Reference><Citation>Dasgupta NR. Care of patients with transthyretin amyloidosis:the roles of nutrition, supplements, exercise, and mental health. Am J Cardiol. 2022;185:S35&#x2013;S42.</Citation><ArticleIdList><ArticleId IdType="pubmed">36549789</ArticleId></ArticleIdList></Reference><Reference><Citation>Argir&#xf2; A, Silverii MV, Burgisser C, Fattirolli F, Baldasseroni S, di Mario C, et al. Serial changes in cardiopulmonary exercise testing parameters in untreated patients with transthyretin cardiac amyloidosis. Can J Cardiol. 2024;40(3):364&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">37793568</ArticleId></ArticleIdList></Reference><Reference><Citation>Banydeen R, Monfort A, Inamo J, Neviere R. Diagnostic and prognostic values of cardiopulmonary exercise testing in cardiac amyloidosis. Front Cardiovasc Med. 2022;9:898033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9207317</ArticleId><ArticleId IdType="pubmed">35734274</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartolini S, Baldasseroni S, Fattirolli F, Silverii MV, Piccioli L, Perfetto F, et al. Poor right ventricular function is associated with impaired exercise capacity and ventilatory efficiency in transthyretin cardiac amyloid patients. Intern Emerg Med. 2021;16(3):653&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">32918156</ArticleId></ArticleIdList></Reference><Reference><Citation>Yunis A, Doros G, Luptak I, Connors LH, Sam F. Use of ventilatory efficiency slope as a marker for increased mortality in wild-type transthyretin cardiac amyloidosis. Am J Cardiol. 2019;124(1):122&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6556126</ArticleId><ArticleId IdType="pubmed">31053293</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantone A, Serenelli M, Sanguettoli F, Maio D, Fabbri G, Dal Passo B, et al. Cardiopulmonary exercise testing predicts prognosis in amyloid cardiomyopathy:a systematic review and meta-analysis. ESC Heart Fail. 2023;10(4):2740&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10375073</ArticleId><ArticleId IdType="pubmed">37264762</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverii MV, Argir&#xf2; A, Baldasseroni S, Fumagalli C, Zampieri M, Guerrieri L, et al. Prognostic value of cardiopulmonary exercise testing in patients with transthyretin cardiac amyloidosis. Intern Emerg Med. 2023;18(2):585&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">36396841</ArticleId></ArticleIdList></Reference><Reference><Citation>Banydeen R, Eggleston R, Deney A, Monfort A, Ryu JH, Vergaro G, et al. Risk stratification in transthyretin cardiac amyloidosis:the added value of lung spirometry. J Clin Med. 2023;3684;12(11)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10254011</ArticleId><ArticleId IdType="pubmed">37297878</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalia T, Acharya P, Chan WC, Sauer AJ, Weidling R, Fritzlen JG, et al. Prognostic role of cardiopulmonary exercise testing in wild-type transthyretin amyloid cardiomyopathy patients treated with tafamidis. J Card Fail. 2021;27(11):1285&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">34280522</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank AM, Horton J, Fleg JL, Fonarow GC, Keteyian S, Goldberg L, et al. Modest increase in peak VO2 is related to better clinical outcomes in chronic heart failure patients:Results from Heart Failure and a Controlled Trial to Investigate Outcomes of Exercise Training. Circ Heart Fail. 2012;5(5):579&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3732187</ArticleId><ArticleId IdType="pubmed">22773109</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhakal BP, Malhotra R, Murphy RM, Pappagianopoulos PP, Baggish AL, Weiner RB, et al. Mechanisms of exercise intolerance in heart failure with preserved ejection fraction:The role of abnormal peripheral oxygen extraction. Circ Heart Fail. 2015;8(2):286&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5771713</ArticleId><ArticleId IdType="pubmed">25344549</ArticleId></ArticleIdList></Reference><Reference><Citation>Clemmensen TS, Soerensen J, Hansson NH, Tolbod LP, Harms HJ, Eiskj&#xe6;r H, et al. Myocardial oxygen consumption and efficiency in patients with cardiac amyloidosis. J Am Heart Assoc. 201;7(21):e009974.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6404209</ArticleId><ArticleId IdType="pubmed">30571379</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapezzi C, Milandri A, Lorenzini M. The complex interplay between systolic and diastolic function at rest and during exercise in heart failure:the case of cardiac amyloidosis. Eur J Heart Fail. 2017;19(11):1466&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">28905503</ArticleId></ArticleIdList></Reference><Reference><Citation>Xin Y, Hu W, Chen X, Hu J, Sun Y, Zhao Y. Prognostic impact of light-chain and transthyretin-related categories in cardiac amyloidosis:A systematic review and meta-analysis. Hellenic J Cardiol. 2019;60(6):375&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">30742933</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakahashi T, Arita T, Yamaji K, Inoue K, Yokota T, Hoshii Y, et al. Impact of clinical and echocardiographic characteristics on occurrence of cardiac events in cardiac amyloidosis as proven by endomyocardial biopsy. Int J Cardiol. 2014;176(3):753&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">25131905</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane T, Fontana M, Martinez-Naharro A, Quarta CC, Whelan CJ, Petrie A, et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation. 2019;140(1):16&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">31109193</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhuiyan T, Helmke S, Patel AR, Ruberg FL, Packman J, Cheung K, et al. Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122i mutations and wild-type transthyretin transthyretin cardiac amyloid study (TRACS) Circ Heart Fail. 2011;4(2):121&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4939845</ArticleId><ArticleId IdType="pubmed">21191093</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruberg FL, Maurer MS, Judge DP, Zeldenrust S, Skinner M, Kim AY, et al. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy:The Transthyretin Amyloidosis Cardiac Study (TRACS) Am Heart J. 2012;164(2):222&#x2013;228.e1.</Citation><ArticleIdList><ArticleId IdType="pubmed">22877808</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller AB, Januzzi JL, O'Neill BJ, Gundapaneni B, Patterson TA, Sultan MB, et al. Causes of cardiovascular hospitalization and death in patients with transthyretin amyloid cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]) Am J Cardiol. 2021;148:146&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">33667442</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin J, Steidley DE, Carlsson M, Mohlim O, Maurer MS. Myocardial contraction fraction by M-mode echocardiography is superior to ejection fraction in predicting mortality in transthyretin amyloidosis. J Card Fail. 2018;24(8):504&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6372291</ArticleId><ArticleId IdType="pubmed">30010028</ArticleId></ArticleIdList></Reference><Reference><Citation>Milani P, Dispenzieri A, Scott CG, Gertz MA, Perlini S, Mussinelli R, et al. Independent prognostic value of stroke volume index in patients with immunoglobulin light chain amyloidosis. Circ Cardiovasc Imaging. 2018;11(5):e006588.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5963522</ArticleId><ArticleId IdType="pubmed">29752392</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng KY, Loungani RS, Rao VN, Patel CB, Khouri MG, Felker GM, et al. Best practices for prognostic evaluation of a patient with transthyretin amyloid cardiomyopathy. JACC CardioOncol. 2019;1(2):273&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8352120</ArticleId><ArticleId IdType="pubmed">34396189</ArticleId></ArticleIdList></Reference><Reference><Citation>Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68(10):1014&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">27585505</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39(30):2799&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pubmed">29048471</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3675680</ArticleId><ArticleId IdType="pubmed">22331953</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillmore JD, Reilly MM, Coats CJ, Cooper R, Cox H, Coyne MRE, et al. Clinical and genetic evaluation of people with or at risk of hereditary ATTR amyloidosis:an expert opinion and consensus on Best Practice in Ireland and the UK. Adv Ther. 2022;39(6):2292&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9122857</ArticleId><ArticleId IdType="pubmed">35419651</ArticleId></ArticleIdList></Reference><Reference><Citation>Grandis M, Obici L, Luigetti M, Briani C, Benedicenti F, Bisogni G, et al. Recommendations for pre-symptomatic genetic testing for hereditary transthyretin amyloidosis in the era of effective therapy:a multicenter Italian consensus. Orphanet J Rare Dis. 2020;15(1):348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7734774</ArticleId><ArticleId IdType="pubmed">33317601</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39250316</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>12</Issue><PubDate><Year>2024</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Localized Administration of Mesenchymal Stem Cell-Derived Exosomes for the Treatment of Refractory Perianal Fistula in Patients With Crohn's Disease: A Phase II Clinical Trial.</ArticleTitle><Pagination><StartPage>1564</StartPage><EndPage>1575</EndPage><MedlinePgn>1564-1575</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003502</ELocationID><Abstract><AbstractText Label="BACKGROUND">Crohn's disease perianal fistulas are often resistant to standard anti-tumor necrosis factor-&#x3b1; therapies. Mesenchymal stem cell-derived exosomes are extracellular vesicles with highly potent anti-inflammatory effects, and the previous phase of this study demonstrated their safety in the treatment of refractory perianal fistulas.</AbstractText><AbstractText Label="OBJECTIVE">To evaluate the efficacy of mesenchymal stem cell-derived exosomes for the treatment of refractory perianal fistulas.</AbstractText><AbstractText Label="DESIGN">Nonrandomized, nonblinded single-center phase II clinical trial.</AbstractText><AbstractText Label="SETTINGS">Tertiary university hospital.</AbstractText><AbstractText Label="PATIENTS">Twenty-three patients were enrolled, 20 of whom completed the study. Refractory perianal fistula was defined as resistance to at least 1 course of treatment with anti-tumor necrosis factor-&#x3b1; therapy.</AbstractText><AbstractText Label="INTERVENTIONS">After clinical assessment and MRI, the patients received general anesthesia, and 5&#x2009;mL of exosome solution was injected directly into the fistula tracts. The injections were repeated 3 times at 2-month intervals, and patients were followed monthly for 6 months after the last injection. Tissue samples from the tracts were obtained before each injection and subjected to immunohistopathological assessment. MRI data were obtained before and 6 months after the last injection.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">The primary outcome of this study was fistula tract closure on clinical examination and MRI. The secondary outcome was an improvement in the discharge from the tracts.</AbstractText><AbstractText Label="RESULTS">Fistula tracts were fully closed in 12 patients (60%). Four patients showed clinical improvement, with some tracts remaining open, and 4 patients were completely resistant to treatment. A total of 43 fistula tracts were treated during the trial, 30 of which (69.7%) showed complete closure. Histopathological analysis revealed substantial reductions in local inflammation and signs of enhanced tissue regeneration. Immunohistochemical analysis of CD68, CD20, and CD31 reaffirmed these results.</AbstractText><AbstractText Label="CONCLUSIONS">Mesenchymal stem cell-derived exosomes are safe and effective for treating refractory perianal fistulas in patients with Crohn's disease. See Video Abstract .</AbstractText><AbstractText Label="ADMINISTRACIN LOCALIZADA DE EXOSOMAS DERIVADOS DE CLULAS MADRE MESENQUIMALES PARA EL TRATAMIENTO DE LA FSTULA PERIANAL REFRACTARIA EN PACIENTES CON ENFERMEDAD DE CROHN ENSAYO CLNICO DE FASE II">ANTECEDENTES:Las f&#xed;stulas perianales de la enfermedad de Crohn a menudo son resistentes a las terapias anti-TNF-&#x3b1; est&#xe1;ndares. Los exosomas derivados de c&#xe9;lulas madre mesenquimales (MSC) son ves&#xed;culas extracelulares que tienen efectos antiinflamatorios muy potentes, y la fase anterior de este estudio demostr&#xf3; su seguridad en el tratamiento de f&#xed;stulas perianales refractarias.OBJETIVO:Evaluar la eficacia de los exosomas derivados de MSC para el tratamiento de f&#xed;stulas perianales refractarias.DISE&#xd1;O:Ensayo cl&#xed;nico de fase II, no aleatorizado y no ciego, unic&#xe9;ntrico.LUGARES:Hospital universitario terciario.PACIENTES:Se inscribieron veintitr&#xe9;s pacientes, 20 de los cuales completaron el estudio. La f&#xed;stula perianal refractaria se defini&#xf3; como la resistencia a al menos un ciclo de tratamiento con terapia anti-TNF-&#x3b1;.INTERVENCIONES:Despu&#xe9;s de la evaluaci&#xf3;n cl&#xed;nica y la resonancia magn&#xe9;tica, los pacientes fueron sometidos a anestesia general y se inyectaron 5&#x2009;ml de soluci&#xf3;n de exosoma directamente en los trayectos de la f&#xed;stula. Las inyecciones se repitieron tres veces a intervalos de 2 meses y los pacientes fueron seguidos mensualmente durante 6 meses despu&#xe9;s de la &#xfa;ltima inyecci&#xf3;n. Se obtuvieron muestras de tejido de los tractos antes de cada inyecci&#xf3;n y se sometieron a evaluaci&#xf3;n inmunohistopatol&#xf3;gica. Los datos de im&#xe1;genes de resonancia magn&#xe9;tica se obtuvieron antes y seis meses despu&#xe9;s de la &#xfa;ltima inyecci&#xf3;n.PRINCIPALES MEDIDAS DE RESULTADO:El resultado primario de este estudio fue el cierre del trayecto de la f&#xed;stula en el examen cl&#xed;nico y la imagen de resonancia magn&#xe9;tica. El resultado secundario fue una mejora en la descarga de los tractos.RESULTADOS:Los trayectos de la f&#xed;stula se cerraron completamente en 12 (60%) de los pacientes. Cuatro pacientes mostraron mejor&#xed;a cl&#xed;nica, algunos tractos permanecieron abiertos y cuatro pacientes fueron completamente resistentes al tratamiento. Durante el ensayo se trataron un total de 43 trayectos fistulosos, 30 (69,7%) de los cuales mostraron un cierre completo. El an&#xe1;lisis histopatol&#xf3;gico revel&#xf3; reducciones sustanciales en la inflamaci&#xf3;n local y signos de una mayor regeneraci&#xf3;n tisular. El an&#xe1;lisis inmunohistoqu&#xed;mico del grupo de diferenciaci&#xf3;n 68, 20 y 31 reafirm&#xf3; estos resultados.CONCLUSIONES:Los exosomas derivados de MSC son seguros y eficaces para el tratamiento de f&#xed;stulas perianales refractarias en pacientes con enfermedad de Crohn. (Traducci&#xf3;n-Dr. Aurian Garcia Gonzalez ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hadizadeh</LastName><ForeName>Alireza</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0821-7557</Identifier><AffiliationInfo><Affiliation>Colorectal Research Center, Imam Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Female Pelvic Medicine and Reconstructive Surgery (FPMRS) Division, University of Chicago Pritzker School of Medicine, Northshore University HealthSystem, Skokie, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akbari Asbagh</LastName><ForeName>Reza</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-9971-2937</Identifier><AffiliationInfo><Affiliation>Colorectal Research Center, Imam Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Colorectal Surgery, Department of Surgery, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heirani-Tabasi</LastName><ForeName>Asieh</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0817-1950</Identifier><AffiliationInfo><Affiliation>Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Center for Advanced Technologies in Cardiovascular Medicine, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soleimani</LastName><ForeName>Masoud</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gorovanchi</LastName><ForeName>Parastou</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-5088-5025</Identifier><AffiliationInfo><Affiliation>Department of Pathology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ebrahimi Daryani</LastName><ForeName>Nasser</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Division of Gastroenterology, Imam Khomeini Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vahedi</LastName><ForeName>Amir</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nazari</LastName><ForeName>Hengameh</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Radiology Department, Mazandaran University of Medical Sciences, Sari, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banikarimi</LastName><ForeName>Seyedeh-Parnian</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Department of Tissue Engineering and Regenerative Medicine, School of Advanced Technologies in Medicine, Mazandaran University of Medical Sciences, Sari, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abbaszade Dibavar</LastName><ForeName>Mahnoosh</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Behboudi</LastName><ForeName>Behnam</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-0632-7090</Identifier><AffiliationInfo><Affiliation>Colorectal Research Center, Imam Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Colorectal Surgery, Department of Surgery, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fazeli</LastName><ForeName>Mohammad Sadegh</ForeName><Initials>MS</Initials><Identifier Source="ORCID">0000-0002-2551-5890</Identifier><AffiliationInfo><Affiliation>Colorectal Research Center, Imam Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Colorectal Surgery, Department of Surgery, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keramati</LastName><ForeName>Mohammad Reza</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Colorectal Research Center, Imam Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Colorectal Surgery, Department of Surgery, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keshvari</LastName><ForeName>Amir</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Colorectal Research Center, Imam Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Colorectal Surgery, Department of Surgery, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kazemeini</LastName><ForeName>Alireza</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-7205-1526</Identifier><AffiliationInfo><Affiliation>Colorectal Research Center, Imam Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Colorectal Surgery, Department of Surgery, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pak</LastName><ForeName>Haleh</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Colorectal Research Center, Imam Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Colorectal Surgery, Department of Surgery, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fazeli</LastName><ForeName>Amir-Reza</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Colorectal Research Center, Imam Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Colorectal Surgery, Department of Surgery, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alborzi Avanaki</LastName><ForeName>Foroogh</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Division of Gastroenterology, Imam Khomeini Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmadi-Tafti</LastName><ForeName>Seyed-Mohsen</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Colorectal Research Center, Imam Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Colorectal Surgery, Department of Surgery, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012003" MajorTopicYN="Y">Rectal Fistula</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003424" MajorTopicYN="Y">Crohn Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055354" MajorTopicYN="Y">Exosomes</DescriptorName><QualifierName UI="Q000637" MajorTopicYN="N">transplantation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045164" MajorTopicYN="Y">Mesenchymal Stem Cell Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059630" MajorTopicYN="Y">Mesenchymal Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Crohn&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Extracellular vesicles</Keyword><Keyword MajorTopicYN="N">IBD</Keyword><Keyword MajorTopicYN="N">Mesenchymal stem cell</Keyword><Keyword MajorTopicYN="N">Perianal fistulas</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>9</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>9</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39250316</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003502</ArticleId><ArticleId IdType="pii">00003453-990000000-00734</ArticleId></ArticleIdList><ReferenceList><Title/><Reference><Citation>Scharl M, Rogler G. Pathophysiology of fistula formation in Crohn&#x2019;s disease. World J Gastrointest Pathophysiol. 2014;5:205&#x2013;212.</Citation></Reference><Reference><Citation>Panes J, Reinisch W, Rupniewska E, et al. Burden and outcomes for complex perianal fistulas in Crohn&#x2019;s disease: systematic review. World J Gastroenterol. 2018;24:4821&#x2013;4834.</Citation></Reference><Reference><Citation>Gold SL, Cohen-Mekelburg S, Schneider Y, Steinlauf A. Perianal fistulas in patients with Crohn&#x2019;s disease, part 1: current medical management. Gastroenterol Hepatol (N Y). 2018;14:470&#x2013;481.</Citation></Reference><Reference><Citation>Parian AM, Obi M, Fleshner P, Schwartz DA. Management of perianal Crohn&#x2019;s disease. Am J Gastroenterol. 2023;118:1323&#x2013;1331.</Citation></Reference><Reference><Citation>Laureti S, Gionchetti P, Cappelli A, et al. Refractory complex Crohn&#x2019;s perianal fistulas: a role for autologous microfragmented adipose tissue injection. Inflamm Bowel Dis. 2020;26:321&#x2013;330.</Citation></Reference><Reference><Citation>Volarevic V, Markovic BS, Gazdic M, et al. Ethical and safety issues of stem cell-based therapy. Int J Med Sci. 2018;15:36&#x2013;45.</Citation></Reference><Reference><Citation>Jafari D, Malih S, Eslami SS, et al. The relationship between molecular content of mesenchymal stem cells derived exosomes and their potentials: opening the way for exosomes based therapeutics. Biochimie. 2019;165:76&#x2013;89.</Citation></Reference><Reference><Citation>Harrell CR, Jovicic N, Djonov V, Arsenijevic N, Volarevic V. Mesenchymal stem cell-derived exosomes and other extracellular vesicles as new remedies in the therapy of inflammatory diseases. Cells. 2019;8:1605.</Citation></Reference><Reference><Citation>Nazari H, Naei VY, Tabasi AH, et al. Advanced regenerative medicine strategies for treatment of perianal fistula in Crohn&#x2019;s disease. Inflamm Bowel Dis. 2022;28:133&#x2013;142.</Citation></Reference><Reference><Citation>Wang J-H, Liu X-L, Sun J-M, Yang J-H, Xu D-H, Yan S-S. Role of mesenchymal stem cell derived extracellular vesicles in autoimmunity: a systematic review. World J Stem Cells. 2020;12:879&#x2013;896.</Citation></Reference><Reference><Citation>Deng H, Sun C, Sun Y, et al. Lipid, protein, and microRNA composition within mesenchymal stem cell-derived exosomes. Cell Reprogram. 2018;20:178&#x2013;186.</Citation></Reference><Reference><Citation>Nazari H, Alborzi F, Heirani-Tabasi A, et al. Evaluating the safety and efficacy of mesenchymal stem cell-derived exosomes for treatment of refractory perianal fistula in IBD patients: clinical trial phase I. Gastroenterol Rep (Oxf). 2022;10:goac075.</Citation></Reference><Reference><Citation>Th&#xe9;ry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7:1535750.</Citation></Reference><Reference><Citation>Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. J Pharmacol Pharmacother. 2010;340:100&#x2013;107. https://doi.org/10.1136/bmj.c332.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.c332</ArticleId></ArticleIdList></Reference><Reference><Citation>Pak H, Hadizadeh A, Heirani&#x2010;Tabasi A, et al. Safety and efficacy of injection of human placenta mesenchymal stem cells derived exosomes for treatment of complex perianal fistula in non&#x2010;Crohn&#x2019;s cases: clinical trial phase I. J Gastroenterol Hepatol. 2023;38:539&#x2013;547.</Citation></Reference><Reference><Citation>Tang Y, Zhou Y, Li H-J. Advances in mesenchymal stem cell exosomes: a review. Stem Cell Res Ther. 2021;12:71.</Citation></Reference><Reference><Citation>Han Y, Ren J, Bai Y, Pei X, Han Y. Exosomes from hypoxia-treated human adipose-derived mesenchymal stem cells enhance angiogenesis through VEGF/VEGF-R. Int J Biochem Cell Biol. 2019;109:59&#x2013;68.</Citation></Reference><Reference><Citation>Hadizadeh AAR, Akbari Asbagh R, Alborzi Avanaki F, et al. Localized administration of mesenchymal stem cell-derived exosomes for treatment of refractory perianal fistula in Crohn&#x2019;s disease patients: phase-II clinical trial [ASCRS abstract M101]. Dis Colon Rectum. 2024;67:e478&#x2013;e479.</Citation></Reference><Reference><Citation>Alessandroni L, Kohn A, Cosintino R, et al. Local injection of infliximab in severe fistulating perianal Crohn&#x2019;s disease: an open uncontrolled study. Tech Coloproctol. 2011;15:407&#x2013;412.</Citation></Reference><Reference><Citation>Duff S, Sagar P, Rao M, et al. Infliximab and surgical treatment of complex anal Crohn&#x2019;s disease. Colorectal Dis. 2012;14:972&#x2013;976.</Citation></Reference><Reference><Citation>Nikfarjam S, Rezaie J, Zolbanin NM, Jafari R. Mesenchymal stem cell derived-exosomes: a modern approach in translational medicine. J Transl Med. 2020;18:449.</Citation></Reference><Reference><Citation>Pan&#xe9;s J, Garc&#xed;a-Olmo D, Van Assche G, et al.; ADMIRE CD Study Group Collaborators. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn&#x2019;s disease: a phase 3 randomised, double-blind controlled trial. Lancet. 2016;388:1281&#x2013;1290.</Citation></Reference><Reference><Citation>Pan&#xe9;s J, Garc&#xed;a-Olmo D, Van Assche G, et al.; ADMIRE CD Study Group Collaborators. Long-term efficacy and safety of stem cell therapy (Cx601) for complex perianal fistulas in patients with Crohn&#x2019;s disease. Gastroenterology. 2018;154:1334&#x2013;1342.e4.</Citation></Reference><Reference><Citation>Peshkova M, Korneev A, Suleimanov S, et al. MSCs&#x2019; conditioned media cytokine and growth factor profiles and their impact on macrophage polarization. Stem Cell Res Ther. 2023;14:142.</Citation></Reference><Reference><Citation>Zhong Y, Zhang Y, Wang Q, Zhang J. Therapeutic role of exosomes and conditioned medium in keloid and hypertrophic scar and possible mechanisms. Front Physiol. 2023;14:1247734.</Citation></Reference><Reference><Citation>Wang C, Chen J. microRNAs as therapeutic targets in intestinal diseases. ExRNA. 2019;1:23.</Citation></Reference><Reference><Citation>Asgarpour K, Shojaei Z, Amiri F, et al. Exosomal microRNAs derived from mesenchymal stem cells: cell-to-cell messages. Cell Commun Signal. 2020;18:149.</Citation></Reference><Reference><Citation>Laurindo LF, Santos A, Carvalho ACA, et al. Phytochemicals and regulation of NF-kB in inflammatory bowel diseases: an overview of in vitro and in vivo effects. Metabolites. 2023;13:96.</Citation></Reference><Reference><Citation>Zheng D, Huo M, Li B, et al. The role of exosomes and exosomal microRNA in cardiovascular disease. Front Cell Dev Biol. 2021;8:616161.</Citation></Reference><Reference><Citation>Wang G, Yuan J, Cai X, et al. HucMSC&#x2010;exosomes carrying miR&#x2010;326 inhibit neddylation to relieve inflammatory bowel disease in mice. Clin Transl Med. 2020;10:e113.</Citation></Reference><Reference><Citation>Cao L, Xu H, Wang G, Liu M, Tian D, Yuan Z. Extracellular vesicles derived from bone marrow mesenchymal stem cells attenuate dextran sodium sulfate-induced ulcerative colitis by promoting M2 macrophage polarization. Int Immunopharmacol. 2019;72:264&#x2013;274.</Citation></Reference><Reference><Citation>Wu X, Xu X, Xiang Y, et al. Exosome-mediated effects and applications in inflammatory diseases of the digestive system. Eur J Med Res. 2022;27:163.</Citation></Reference><Reference><Citation>Lei H, Crawford MS, McCole DF. JAK-STAT pathway regulation of intestinal permeability: pathogenic roles and therapeutic opportunities in inflammatory bowel disease. Pharmaceuticals (Basel). 2021;14:840.</Citation></Reference><Reference><Citation>Lalu MM, McIntyre L, Pugliese C, et al.; Canadian Critical Care Trials Group. Safe ty of cell therapy with mesenchymal stromal cells (safecell): a systematic review and meta-analysis of clinical trials. PLoS One. 2012;7:e47559.</Citation></Reference><Reference><Citation>Sun L, Xu R, Sun X, et al. Safety evaluation of exosomes derived from human umbilical cord mesenchymal stromal cell. Cytotherapy. 2016;18:413&#x2013;422.</Citation></Reference><Reference><Citation>Park H-s, Chugh RM, Seok J, et al. Comparison of the therapeutic effects between stem cells and exosomes in primary ovarian insufficiency: as promising as cells but different persistency and dosage. Stem Cell Res Ther. 2023;14:165.</Citation></Reference><Reference><Citation>Garcia-Arranz M, Garcia-Olmo D, Herreros MD, et al.; FISPAC Collaborative Group. Autologous adipose-derived stem cells for the treatment of complex cryptoglandular perianal fistula: a randomized clinical trial with long-term follow-up. Stem Cells Transl. Med. 2020;9:295&#x2013;301.</Citation></Reference><Reference><Citation>Molendijk I, Bonsing BA, Roelofs H, et al. Allogeneic bone marrow&#x2013;derived mesenchymal stromal cells promote healing of refractory perianal fistulas in patients with Crohn&#x2019;s disease. Gastroenterology. 2015;149:918&#x2013;927.</Citation></Reference><Reference><Citation>Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow&#x2013;derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012;308:2369&#x2013;2379.</Citation></Reference><Reference><Citation>Sun C, Hao J, Qin H, et al. Endometrial regenerative cell&#x2010;derived conditioned medium alleviates experimental colitis. Stem Cells Int. 2022;2022:7842296.</Citation></Reference><Reference><Citation>Eder P, Lykowska-Szuber L, Iwanik K, et al. The influence of anti-TNF therapy on CD31 and VEGF expression in colonic mucosa of Crohn&#x2019;s disease patients in relation to mucosal healing. Folia Histochem Cytobiol. 2016;54:75&#x2013;80.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38590383</PMID><DateRevised><Year>2024</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2352-9067</ISSN><JournalIssue CitedMedium="Print"><Volume>52</Volume><PubDate><Year>2024</Year><Month>Jun</Month></PubDate></JournalIssue><Title>International journal of cardiology. Heart &amp; vasculature</Title><ISOAbbreviation>Int J Cardiol Heart Vasc</ISOAbbreviation></Journal><ArticleTitle>Cardiovascular testing recovery in Latin America one year into the COVID-19 pandemic: An analysis of data from an international longitudinal survey.</ArticleTitle><Pagination><StartPage>101404</StartPage><MedlinePgn>101404</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">101404</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijcha.2024.101404</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The COVID-19 pandemic disproportionately impacted Latin America (LATAM), significantly disrupting cardiovascular testing. This study evaluated cardiac procedure recovery in LATAM one year after the outbreak.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">The International Atomic Energy Agency (IAEA) surveyed 669 centers in 107 countries worldwide, including 135 facilities in 19 LATAM countries, to assess cardiovascular procedure volumes in March 2019, April 2020, and April 2021, and changes in center practices and staffing conditions one year into the COVID-19 pandemic.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="UNASSIGNED">LATAM centers reported a 21&#xa0;% decrease in procedure volumes in April 2021 from pre-pandemic-baseline, vs. a 0&#xa0;% change in the rest of the world (RoW), and greater volume reductions for almost all procedure types. Centers in Central America and Mexico reported the largest procedure reductions (47&#xa0;% reduction) compared to the Caribbean (15&#xa0;%), and South America (14&#xa0;%, p&#xa0;=&#xa0;0.01), and this LATAM region was a significant predictor of lower procedure recovery in multivariable regression. More LATAM centers reported reduced salaries and increased layoffs of clinical staff compared to RoW, and LATAM respondents estimated that half of physician and non-physician staff experienced excess psychological stress related to the pandemic, compared to 25&#xa0;% and 30&#xa0;% in RoW (p&#xa0;&lt;&#xa0;0.001).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Cardiovascular testing recovery in LATAM trailed behind RoW for most procedure types, with centers in Central America and Mexico reporting the greatest volume reductions. This study found lasting impacts of COVID-19 on cardiovascular care in LATAM and the need for mental health support for LATAM healthcare workers in current and future pandemics.</AbstractText><CopyrightInformation>Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bremner</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vitola</LastName><ForeName>Joao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Quanta Diagnostico, Curitiba, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cerci</LastName><ForeName>Rodrigo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Quanta Diagnostico, Curitiba, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campisi</LastName><ForeName>Roxana</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Diagn&#xf3;stico Maip&#xfa; and Instituto Argentino de Diagn&#xf3;stico Y Tratamiento S.A., Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Araujo R&#xed;os</LastName><ForeName>Ra&#xfa;l</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Instituto de Medicina Nuclear, Sucre, Bolivia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Massardo</LastName><ForeName>Teresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Hospital Clinico Universidad de Chile, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gutierrez-Villamil</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Fundacion Cardioinfantil, Instituto de Cardiologia, Bogota, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solis</LastName><ForeName>Felix</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Hospital Escalante Pradilla, Perez Zeledon, Costa Rica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peix</LastName><ForeName>Amalia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Cardiology and Cardiovascular Surgery, La Habana, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Speckter</LastName><ForeName>Herwin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Cedimat, Santo Domingo, Dominican Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez Velez</LastName><ForeName>Mayra</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sociedad Ecuatoriana de Cardiolog&#xed;a Y a La Sociedad Espa&#xf1;ola de Imagen Card&#xed;aca, Ecuador.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flores</LastName><ForeName>Ana Camila</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Clinica de Radiologia Brito Mejia Pe&#xf1;a, San Salvador, El Salvador.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madu</LastName><ForeName>Ernest</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Heart Institute of the Caribbean and HIC Heart Hospital, Kingston, Jamaica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alex&#xe1;nderson-Rosas</LastName><ForeName>Erick</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Cardiologia Ignacio Chavez, Ciudad de Mexico, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ortellado</LastName><ForeName>Jos&#xe9;</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Central Hospital, Social Institute, Asunci&#xf3;n, Paraguay.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morales</LastName><ForeName>Rosanna</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Departamento de Medicina Nuclear, Instituto Nacional de Enfermedades Neopl&#xe1;sicas, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mut</LastName><ForeName>Fernando</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Italian Hospital, Montevideo, Uruguay.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vera</LastName><ForeName>Luisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Urologico San Roman, Caracas, Venezuela.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirschfeld</LastName><ForeName>Cole B</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Leslee J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Blavatnik Family Women's Health Research Institute, Mount Sinai Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Michelle C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>BHF Centre for Cardiovascular Science, University of Edinburgh, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villines</LastName><ForeName>Todd C</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Medicine, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Better</LastName><ForeName>Nathan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Cabrini Health, Royal Melbourne Hospital, Monash University and University of Melbourne, Melbourne, Australia, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dorbala</LastName><ForeName>Sharmila</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Departments of Medicine and Radiology, Brigham and Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karthikeyan</LastName><ForeName>Ganesan</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Cardiology, All India Institute of Medical Sciences, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malkovskiy</LastName><ForeName>Eli</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Seymour, Paul and Gloria Milstein Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center and NewYork-Presbyterian Hospital, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Yosef A</ForeName><Initials>YA</Initials><AffiliationInfo><Affiliation>Seymour, Paul and Gloria Milstein Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center and NewYork-Presbyterian Hospital, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Columbia University Mailman School of Public Health, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Children's Hospital at Montefiore, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Randazzo</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Section of Cardiology, University of Chicago Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pascual</LastName><ForeName>Thomas N B</ForeName><Initials>TNB</Initials><AffiliationInfo><Affiliation>Philippine Nuclear Research Institute, Quezon City, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pynda</LastName><ForeName>Yaroslav</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Human Health, Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dondi</LastName><ForeName>Maurizio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Human Health, Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paez</LastName><ForeName>Diana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Human Health, Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Einstein</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Seymour, Paul and Gloria Milstein Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center and NewYork-Presbyterian Hospital, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Columbia University Irving Medical Center and New York-Presbyterian Hospital, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>INCAPS COVID</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>2</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Investigators Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>04</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Int J Cardiol Heart Vasc</MedlineTA><NlmUniqueID>101649525</NlmUniqueID><ISSNLinking>2352-9067</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Cardiac testing</Keyword><Keyword MajorTopicYN="N">Cardiovascular disease</Keyword><Keyword MajorTopicYN="N">Cardiovascular imaging</Keyword><Keyword MajorTopicYN="N">Coronavirus</Keyword><Keyword MajorTopicYN="N">Global health</Keyword></KeywordList><CoiStatement>The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [Dr. Massardo has been supported by Pfizer for educational activities related to ATTR amyloidosis and has participated in two multicenter research projects supported by Pfizer. Dr. Williams has given talks for Canon Medical Systems, Siemens Healthineers and Novartis and is supported by the British Heart Foundation (FS/ICRF/20/26002). Dr. Villines is a current employee of Elucid Biomining, Inc that is unrelated to this work. Dr. Dorbala has received honoraria from Pfizer and GE Healthcare; and has received grants to her institution from Pfizer and GE Healthcare. Dr. Einstein has received fees for speaking from Ionetix, consulting from W. L. Gore &amp; Associates, serving on a scientific advisory committee for Canon Medical Systems USA, and authorship from Wolters Kluwer Healthcare &#x2013; UpToDate; has grants/grants pending from Attralus, Canon Medical Systems USA, Eidos Therapeutics, GE Healthcare, Pfizer, Roche Medical Systems, W. L. Gore &amp; Associates, XyloCor Therapeutics, Neovasc, Intellia Therapeutics, Ionis Pharmaceuticals, the National Institutes of Health, and the IAEA. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose].</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>3</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>9</Day><Hour>3</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>4</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38590383</ArticleId><ArticleId IdType="pmc">PMC11000160</ArticleId><ArticleId IdType="doi">10.1016/j.ijcha.2024.101404</ArticleId><ArticleId IdType="pii">S2352-9067(24)00070-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rivera-Andrade A., Luna M.A. Trends and heterogeneity of cardiovascular disease and risk factors across latin American and caribbean countries. Prog Cardiovasc Dis. 2014;57(3):276&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">25218566</ArticleId></ArticleIdList></Reference><Reference><Citation>Feigin V.L., Forouzanfar M.H., Krishnamurthi R., et al. Global and regional burden of stroke during 1990&#x2013;2010: findings from the global burden of disease study 2010. Lancet. 2014;383(9913):245&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4181600</ArticleId><ArticleId IdType="pubmed">24449944</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulati M., Levy P.D., Mukherjee D., et al. AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR guideline for the evaluation and diagnosis of chest pain. J Am Coll Cardiol. 2021;78(22):e187&#x2013;e285.</Citation><ArticleIdList><ArticleId IdType="pubmed">34756653</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnett D.K., Blumenthal R.S., Albert M.A., et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the american college of cardiology/american heart association task force on clinical practice guidelines. Circulation. 2019;140(11):e596&#x2013;e646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7734661</ArticleId><ArticleId IdType="pubmed">30879355</ArticleId></ArticleIdList></Reference><Reference><Citation>Einstein A.J., Shaw L.J., Hirschfeld C., et al. International impact of COVID-19 on the diagnosis of Heart disease. J Am Coll Cardiol. 2021;77(2):173&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7836433</ArticleId><ArticleId IdType="pubmed">33446311</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin A.T., Owusu-Boaitey N., Pugh S., et al. Assessing the burden of COVID-19 in developing countries: systematic review, meta-analysis and public policy implications. BMJ Glob Health. 2022;7(5):e008477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9136695</ArticleId><ArticleId IdType="pubmed">35618305</ArticleId></ArticleIdList></Reference><Reference><Citation>Batista C., Hotez P., Amor Y.B., et al. The silent and dangerous inequity around access to COVID-19 testing: a call to action. EClinicalMedicine. 2022;43 doi: 10.1016/j.eclinm.2021.101230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101230</ArticleId><ArticleId IdType="pmc">PMC8668028</ArticleId><ArticleId IdType="pubmed">34927038</ArticleId></ArticleIdList></Reference><Reference><Citation>Duroseau B., Kipshidze N., Limaye R.J. The impact of delayed access to COVID-19 vaccines in low- and lower-middle-income countries. Front Public Health. 2023;10:1087138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9878283</ArticleId><ArticleId IdType="pubmed">36711400</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 Test tracker. Available from: https://www.finddx.org/tools-and-resources/dxconnect/test-directories/covid-19-test-tracker/. Date accessed. July 5, 2023.</Citation></Reference><Reference><Citation>UNDP Data Futures Platform. Global Dashboard for Vaccine Equity. Available from: https://data.undp.org/vaccine-equity/. Date accessed: July 5, 2023.</Citation></Reference><Reference><Citation>Einstein A.J., Hirschfeld C., Williams M.C., et al. Worldwide disparities in recovery of cardiac testing 1 Year into COVID-19. J Am Coll Cardiol. 2022;79(20):2001&#x2013;2017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9109706</ArticleId><ArticleId IdType="pubmed">35589162</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamin E.J., Blaha M.J., Chiuve S.E., et al. Heart disease and stroke statistics&#x2014;2017 update. Circulation. 2017;135(10):e146&#x2013;e603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5408160</ArticleId><ArticleId IdType="pubmed">28122885</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirtz V.J., Kaplan W.A., Kwan G.F., Laing R.O. Access to medications for cardiovascular diseases in low- and middle-income countries. Circulation. 2016;133(21):2076&#x2013;2085.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4880457</ArticleId><ArticleId IdType="pubmed">27217433</ArticleId></ArticleIdList></Reference><Reference><Citation>World Bank Open Data. Available from: https://data.worldbank.org. Date accessed July 8, 2023.</Citation></Reference><Reference><Citation>Reuters. The latest global coronavirus statistics, charts and maps. Available from: https://www.reuters.com/world-coronavirus-tracker-and-maps/. Date accessed: July 8, 2023.</Citation></Reference><Reference><Citation>Cerci R.J., Vitola J.V., Paez D., et al. The impact of COVID-19 on diagnosis of Heart disease in Latin America an INCAPS COVID sub-analysis. Arq Bras Cardiol. 2022;118:745&#x2013;753.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9007020</ArticleId><ArticleId IdType="pubmed">35137793</ArticleId></ArticleIdList></Reference><Reference><Citation>IAEA. IRIS. Available from: https://iris.iaea.org/#pages/welcome.html. Date accessed: July 8, 2023.</Citation></Reference><Reference><Citation>UNSD &#x2014; Methodology. Available from: https://unstats.un.org/unsd/methodology/m49. Date accessed: July 21, 2023.</Citation></Reference><Reference><Citation>Stata Bookstore. Base Reference Manual, Release 18. Available from: https://www.stata.com/bookstore/base-reference-manual/. Date accessed: July 13, 2023.</Citation></Reference><Reference><Citation>Schwalb A., Armyra E., M&#xe9;ndez-Aranda M., Ugarte-Gil C. COVID-19 in Latin America and the Caribbean: two years of the pandemic. J Intern Med. 2022;292(3):409&#x2013;427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9115176</ArticleId><ArticleId IdType="pubmed">35411985</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia P.J., Alarc&#xf3;n A., Bayer A., et al. COVID-19 response in Latin America. Am J Trop Med Hyg. 2020;103(5):1765&#x2013;1772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7646820</ArticleId><ArticleId IdType="pubmed">32940204</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayol J., Artucio C., Batista I., et al. An international survey in Latin America on the practice of interventional cardiology during the COVID-19 pandemic, with a particular focus on myocardial infarction. Neth Heart J. 2020;28(7):424&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7325476</ArticleId><ArticleId IdType="pubmed">32607704</ArticleId></ArticleIdList></Reference><Reference><Citation>Freudenberg L.S., Paez D., Giammarile F., et al. Global impact of COVID-19 on nuclear medicine departments: an international survey in april 2020. J Nucl Med. 2020;61(9):1278&#x2013;1283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7456173</ArticleId><ArticleId IdType="pubmed">32709733</ArticleId></ArticleIdList></Reference><Reference><Citation>Giammarile F., Delgado Bolton R.C., El-Haj N., et al. Impact of COVID-19 on nuclear medicine departments in Africa and Latin America. Semin Nucl Med. 2022;52(1):31&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8639221</ArticleId><ArticleId IdType="pubmed">34243907</ArticleId></ArticleIdList></Reference><Reference><Citation>Liga R., Gimelli A. Cardiac imaging on COVID-19 pandemic era: the stand, the lost, and found. Curr Cardiovasc Imaging Rep. 2022;15(3):23&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9142344</ArticleId><ArticleId IdType="pubmed">35668865</ArticleId></ArticleIdList></Reference><Reference><Citation>IAEA. Medical Radioisotopes still Produced but Facing Distribution Challenges Globally, Data Collected by IAEA: 2020. Available from https://www.iaea.org/newscenter/news/medical-radioisotopes-still-produced-but-facing-distribution-challenges-globally-data-collected-by-iaea-shows. Date accessed: July 13, 2023.</Citation></Reference><Reference><Citation>Pi&#xf1;a P., Reyes G., Velazco MP., et al. Physicians&#x2019; perceptions on the impact of COVID-19 in coronary artery disease diagnostic imaging and treatment: a Latin America survey. for the society of cardiovascular imaging of the inter-american society of cardiology. IJC Heart Vasc. 2022;40:101015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8958162</ArticleId><ArticleId IdType="pubmed">35372663</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Paulson K.R., Pease S.A., et al. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020&#x2013;21. Lancet. 2022;399(10334):1513&#x2013;1536.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8912932</ArticleId><ArticleId IdType="pubmed">35279232</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Valle A. Public health matters: why is Latin America struggling in addressing the pandemic? J Public Health Policy. 2021;42(1):27&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7841039</ArticleId><ArticleId IdType="pubmed">33510400</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathieu E, Ritchie H, Rod&#xe9;s-Guirao L, et al. Coronavirus Pandemic (COVID-19). Our World Data. Available from: https://ourworldindata.org/covid-cases. Date accessed: July 7, 2023.</Citation></Reference><Reference><Citation>World Bank Open Data. Available from: https://data.worldbank.org. Date accessed: July 8, 2023.</Citation></Reference><Reference><Citation>Chooi Y.C., Ding C., Magkos F. The epidemiology of obesity. Metabolism. 2019;92:6&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">30253139</ArticleId></ArticleIdList></Reference><Reference><Citation>Booth A., Reed A.B., Ponzo S., et al. Population risk factors for severe disease and mortality in COVID-19: a global systematic review and meta-analysis. PLoS One. 2021;16(3):e0247461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7932512</ArticleId><ArticleId IdType="pubmed">33661992</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan W. jie, Liang W hua, Zhao Y., et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):2000547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7098485</ArticleId><ArticleId IdType="pubmed">32217650</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero P.E., D&#xe1;vila-Barclay A., Salvatierra G., et al. The emergence of sars-CoV-2 variant lambda (C.37) in South America. Microbiol Spectr. 2021;9(2):e00789&#x2013;e00821.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8549758</ArticleId><ArticleId IdType="pubmed">34704780</ArticleId></ArticleIdList></Reference><Reference><Citation>Our World in Data. COVID-19 Data Explorer. Available from: https://ourworldindata.org/explorers/coronavirus-data-explorer. Date accessed: July 14, 2023.</Citation></Reference><Reference><Citation>Bartlett J. Chile imposes lockdowns to fight new Covid wave despite vaccination success. The Guardian. 2021 Mar 28: Available from: https://www.theguardian.com/global-development/2021/mar/28/chile-coronavirus-lockdowns-vaccination-success. Date accessed: July 14, 2023.</Citation></Reference><Reference><Citation>Thienemann F., Pinto F., Grobbee D.E., et al. World Heart federation briefing on prevention: coronavirus disease 2019 (COVID-19) in low-income countries. Glob Heart. 2020;15(1):31. doi: 10.5334/gh.778.</Citation><ArticleIdList><ArticleId IdType="doi">10.5334/gh.778</ArticleId><ArticleId IdType="pmc">PMC7218761</ArticleId><ArticleId IdType="pubmed">32489804</ArticleId></ArticleIdList></Reference><Reference><Citation>Beccaria L., Bertranou F., Maurizio R. COVID-19 in Latin America: the effects of an unprecedented crisis on employment and income. Int Labour Rev. 2022;161(1):83&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9111616</ArticleId><ArticleId IdType="pubmed">35603262</ArticleId></ArticleIdList></Reference><Reference><Citation>Abelda&#xf1;o Zu&#xf1;iga R.A., Juanillo-Maluenda H., S&#xe1;nchez-Bandala M.A., Burgos G.V., M&#xfc;ller S.A., Rodr&#xed;guez L&#xf3;pez J.R. Mental health burden of the COVID-19 pandemic in healthcare workers in four latin american countries. Inq J Health Care Organ Provis Financ. 2021;58</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8655476</ArticleId><ArticleId IdType="pubmed">34865558</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosales Vaca K.M., Cruz Barrientos O.I., Gir&#xf3;n L&#xf3;pez S., et al. Mental health of healthcare workers of latin American countries: a review of studies published during the first year of COVID-19 pandemic. Psychiatry Res. 2022;311</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8900936</ArticleId><ArticleId IdType="pubmed">35320759</ArticleId></ArticleIdList></Reference><Reference><Citation>Irarrazaval M., Norambuena P., Montenegro C., Toro-Devia O., Vargas B., Caqueo-Ur&#xed;zar A. Public policy responses to address the mental health consequences of the COVID-19 pandemic: evidence from Chile. Front Public Health. 2021;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8511669</ArticleId><ArticleId IdType="pubmed">34660500</ArticleId></ArticleIdList></Reference><Reference><Citation>Peix A., Mesquita C.T., Guti&#xe9;rrez C., et al. Current status of nuclear cardiology practice in Latin America and the Caribbean, in the era of multimodality cardiac imaging approach: 2022 update. Nucl Med Commun. 2022;43(12):1163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9645550</ArticleId><ArticleId IdType="pubmed">36266992</ArticleId></ArticleIdList></Reference><Reference><Citation>IAEA IMAGINE. Available from: https://public.tableau.com/views/IMAGINE-NAHUNET-CTScanners/CTScanners?:embed=y&amp;:showVizHome=no&amp;:host_url=https%3A%2F%2Fpublic.tableau.com%2F&amp;:embed_code_version=3&amp;:tabs=no&amp;:toolbar=yes&amp;:animate_transition=yes&amp;:display_static_image=no&amp;:display_spinner=no&amp;:display_overlay=yes&amp;:display_count=yes&amp;:language=en-GB&amp;:loadOrderID=0. Date accessed: July 26, 2023.</Citation></Reference><Reference><Citation>Columbia Department of Radiology. A Decade of Global Health Efforts in Haiti Shows Results for Radiology. Available from: https://www.columbiaradiology.org/news/decade-global-health-efforts-haiti-shows-results-radiology. Date accessed: July 21, 2023.</Citation></Reference><Reference><Citation>Haiti Radiology Relief. Available from: https://www.acr.org/Member-Resources/Volunteer/international-outreach/Haiti-Radiology-Relief. Date accessed: July 24, 2023.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33451922</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2253-8089</ISSN><JournalIssue CitedMedium="Internet"><Volume>40</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Season>May-Jun</Season></PubDate></JournalIssue><Title>Revista espanola de medicina nuclear e imagen molecular</Title><ISOAbbreviation>Rev Esp Med Nucl Imagen Mol (Engl Ed)</ISOAbbreviation></Journal><ArticleTitle>The role of <sup>18</sup>F-FDG PET/CT in the management of Merkel cell carcinoma: The experience of 51 studies in our institution.</ArticleTitle><Pagination><StartPage>139</StartPage><EndPage>148</EndPage><MedlinePgn>139-148</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.remn.2020.11.012</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2253-654X(20)30217-1</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine tumor with limited evidence on the role of <sup>18</sup>F-FDG PET/CT. The aim of this study was to assess the impact of the <sup>18</sup>F-FDG PET/CT in the management of MCC.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Fifty-one studies of <sup>18</sup>F-FDG PET/CT of 35 patients (19 men [54.30%]; 72.17&#xb1;14.63years) with histologic diagnosis of MCC were retrospectively evaluated. The change in tumor staging and the impact on the treatment were analysed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There were 23 PET/CT positive studies (45.10%) and 28 (54.90%) negative. Thirty four (66.7%) studies were performed for assessment of stage at initial presentation and 17 (33.3%) were performed during the follow up: 6 (35.29%) for suspected recurrence; 7 (41.18%) for restaging; 4 (23.53%) as a part of ongoing surveillance. On the basis of PET/CT results, there was a change in disease stage (SC) in 20 studies (39.20%) and impact in the management (MI) in 28 (54.90%): 11 (32.40%) SC and 12 (35.30%) MI in the initial staging; 5 (71.43%) SC and 7 (100%) MI in the restaging; 3 (50.00%) SC and 6 (100%) MI in suspected recurrence; 1 (25.00%) SC and 3 (75.00%) MI in the surveillance. <sup>18</sup>F-FDG PET/CT incidentally detected one additional histologically confirmed cancer. The presence of nodal involvement in the beginning (0.0098; HR 3.82; 95%CI: 1.38-10.6), chemotherapy treatment (6e-04; HR 7.06; 95%CI: 2.30-21.60), size of primary tumor &gt;2cm (6e-04; HR 7.06; 95%CI: 2.30-21.60) and positive resection margin (0.00069; HR 4.01; 95%CI: 1.46-11.00) were statistically significant prognostic factors for overall survival. There was a trend towards significance for worse overall survival with initial positive <sup>18</sup>F-FDG PET/CT but the trend did not reach statistical significance.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS"><sup>18</sup>F-FDG PET/CT altered the stage in 2 out of 5 studies and changed the treatment in more than half of the studies performed. The study confirms the important impact of <sup>18</sup>F-FDG PET/CT on the management of MCC patients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Sociedad Espa&#xf1;ola de Medicina Nuclear e Imagen Molecular. Publicado por Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>L&#xf3;pez Prior</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Servicio de Medicina Nuclear, Fundaci&#xf3;n Instituto Valenciano de Oncolog&#xed;a, Valencia, Espa&#xf1;a. Electronic address: loprive@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Llombart Cussac</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Servicio de Dermatolog&#xed;a, Fundaci&#xf3;n Instituto Valenciano de Oncolog&#xed;a, Valencia, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Papel de la <sup>18</sup>F-FDG PET/TC en el manejo del carcinoma de c&#xe9;lulas de Merkel: experiencia de 51 estudios en nuestra instituci&#xf3;n.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Rev Esp Med Nucl Imagen Mol (Engl Ed)</MedlineTA><NlmUniqueID>101770941</NlmUniqueID><ISSNLinking>2253-8089</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">(18)F-FDG PE/CT</Keyword><Keyword MajorTopicYN="N">(18)F-FDG PET/TC</Keyword><Keyword MajorTopicYN="N">Carcinoma de c&#xe9;lulas de Merkel</Keyword><Keyword MajorTopicYN="N">Estadificaci&#xf3;n</Keyword><Keyword MajorTopicYN="N">Impact on management</Keyword><Keyword MajorTopicYN="N">Impacto en el tratamiento</Keyword><Keyword MajorTopicYN="N">Merkel cell carcinoma</Keyword><Keyword MajorTopicYN="N">Staging</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>16</Day><Hour>5</Hour><Minute>31</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33451922</ArticleId><ArticleId IdType="doi">10.1016/j.remn.2020.11.012</ArticleId><ArticleId IdType="pii">S2253-654X(20)30217-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32952176</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>03</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1665-1731</ISSN><JournalIssue CitedMedium="Internet"><Volume>90</Volume><Issue>3</Issue><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>Archivos de cardiologia de Mexico</Title><ISOAbbreviation>Arch Cardiol Mex</ISOAbbreviation></Journal><ArticleTitle>Cardiac amyloidosis: a review of a series of cases.</ArticleTitle><Pagination><StartPage>259</StartPage><EndPage>265</EndPage><MedlinePgn>259-265</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.24875/ACM.19000238</ELocationID><Abstract><AbstractText Label="ANTECEDENTES Y OBJETIVO">La amiloidosis card&#xed;aca es una entidad que permanece infradiagnosticada, a pesar de los avances recientes en su diagn&#xf3;stico y tratamiento. El objetivo de este estudio es revisar una serie de casos de amiloidosis card&#xed;aca para describir los principales datos cl&#xed;nicos y los hallazgos en las pruebas de imagen.</AbstractText><AbstractText Label="MATERIALES Y M&#xc9;TODOS">Estudio retrospectivo de pacientes con diagn&#xf3;stico principal o secundario de amiloidosis card&#xed;aca en los informes de alta de pacientes hospitalizados en este centro desde 2006 hasta 2016. Se revisaron los datos cl&#xed;nicos de los pacientes, as&#xed; como las pruebas de imagen (ECG, ecocardiograma, gammagraf&#xed;a card&#xed;aca, resonancia magn&#xe9;tica card&#xed;aca). Se realiz&#xf3; seguimiento de los pacientes hasta enero de 2018.</AbstractText><AbstractText Label="RESULTADOS">Se analiza a 30 pacientes (20 varones) con media de 65 a&#xf1;os. Los principales datos ecocardiogr&#xe1;ficos fueron dilataci&#xf3;n biauricular, disfunci&#xf3;n diast&#xf3;lica e hipertrofia ventricular izquierda (HVI) en un 97%. S&#xf3;lo el 6.7% cumpl&#xed;a criterios de HVI en el electrocardiograma. Hasta un 33% ten&#xed;a disfunci&#xf3;n sist&#xf3;lica. Se realiz&#xf3; gammagraf&#xed;a y resonancia magn&#xe9;tica card&#xed;aca en un 33%. La supervivencia a los 12 meses fue de 61%.</AbstractText><AbstractText Label="CONCLUSI&#xd3;N">La presencia de insuficiencia card&#xed;aca, fibrilaci&#xf3;n auricular o trastornos de conducci&#xf3;n junto a datos ecocardiogr&#xe1;ficos indicativos debe alertar al cl&#xed;nico. Otros datos como disfunci&#xf3;n sist&#xf3;lica o sexo femenino no deben disminuir la sospecha. El estudio debe completarse con gammagraf&#xed;a y resonancia magn&#xe9;tica card&#xed;aca, ya que el diagn&#xf3;stico temprano tiene implicaciones pron&#xf3;sticas y terap&#xe9;uticas.</AbstractText><AbstractText Label="BACKGROUND AND OBJECTIVE">Cardiac amyloidosis is an entity that remains underdiagnostic, despite recent advances in its diagnosis and treatment. The aim of this study is to review a series of diagnosed cases of cardiac amyloidosis to describe the main clinical data and the findings in the imaging tests.</AbstractText><AbstractText Label="MATERIALS AND METHODS">Retrospective study of patients with primary or secondary diagnosis of cardiac amyloidosis in discharge reports of patients hospitalized in our center from 2006 to 2016. The clinical data of the patients were reviewed, as well as the imaging tests (ECG, echocardiogram, cardiac scintigraphy, cardiac magnetic resonance). Patients were followed until January 2018.</AbstractText><AbstractText Label="RESULTS">We analyze 30 patients (20 men) with an average of 65 years. The main echocardiographic data were biatrial dilatation, diastolic dysfunction and left ventricular hypertrophy (LVH) in 97%. Only 6.7% met criteria for LVH in the electrocardiogram. Up to 33% had systolic dysfunction. Scintigraphy and cardiac magnetic resonance were performed in 33%. Survival at 12 months was 61%.</AbstractText><AbstractText Label="CONCLUSION">The presence of heart failure, atrial fibrillation or conduction disorders with suggestive echocardiographic data should alert the clinician. Other data such as systolic dysfunction or female sex should not decrease the suspicion. The study should be completed with gammagraphy and cardiac magnetic resonance since early diagnosis has prognostic and therapeutic implications.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2020 Permanyer.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Povar-Echeverr&#xed;a</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Servicio de Medicina Interna. Hospital Universitario Miguel Servet, Zaragoza, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Auquilla-Clavijo</LastName><ForeName>Pablo E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Servicio de Cardiolog&#xed;a. Hospital Universitario Miguel Servet, Zaragoza, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Povar-Marco</LastName><ForeName>Bienvenido J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Servicio de Urgencias. Hospital Universitario Miguel Servet, Zaragoza, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreno-Esteban</LastName><ForeName>Eva M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Servicio de Cardiolog&#xed;a. Hospital Universitario Miguel Servet, Zaragoza, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Figueras-Villalba</LastName><ForeName>Mar&#xed;a P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Servicio de Medicina Interna. Hospital Universitario Miguel Servet, Zaragoza, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Amiloidosis card&#xed;aca: revisi&#xf3;n de una serie de casos.</VernacularTitle></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Arch Cardiol Mex</MedlineTA><NlmUniqueID>101126728</NlmUniqueID><ISSNLinking>1665-1731</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="N">Amyloidosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004452" MajorTopicYN="N">Echocardiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004562" MajorTopicYN="N">Electrocardiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006331" MajorTopicYN="N">Heart Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011877" MajorTopicYN="N">Radionuclide Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">99mTc-DPD gammagraf&#xed;a</Keyword><Keyword MajorTopicYN="N">99mTc-DPD scintigraphy</Keyword><Keyword MajorTopicYN="N">Amiloidosis</Keyword><Keyword MajorTopicYN="N">Amyloidosis</Keyword><Keyword MajorTopicYN="N">Cardiomiopathy</Keyword><Keyword MajorTopicYN="N">Heart failure</Keyword><Keyword MajorTopicYN="N">Insuficiencia card&#xed;aca</Keyword><Keyword MajorTopicYN="N">Miocardiopat&#xed;a</Keyword><Keyword MajorTopicYN="N">Transthyretin</Keyword><Keyword MajorTopicYN="N">Transtirretina</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32952176</ArticleId><ArticleId IdType="doi">10.24875/ACM.19000238</ArticleId><ArticleId IdType="pii">j90/3/259</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">32499017</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1885-5857</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Revista espanola de cardiologia (English ed.)</Title><ISOAbbreviation>Rev Esp Cardiol (Engl Ed)</ISOAbbreviation></Journal><ArticleTitle>Changes in the diagnosis and management of acute aortic syndrome and associated mortality in the last 20 years.</ArticleTitle><Pagination><StartPage>257</StartPage><EndPage>262</EndPage><MedlinePgn>257-262</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.rec.2020.02.015</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1885-5857(20)30180-8</ELocationID><Abstract><AbstractText Label="INTRODUCTION AND OBJECTIVES" NlmCategory="OBJECTIVE">Mortality is high in acute aortic syndrome (AAS), which therefore requires early treatment. This study aimed to analyze changes in the diagnosis and treatment of AAS over 20 years at our center.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">From 1999 to 2018, 451 patients diagnosed with AAS (336 men; mean age, 60.9&#xb1;12.4 years) were prospectively included (270 type A and 181 type B). Clinical variables, diagnosis, treatment, and in-hospital complications were analyzed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The use of computed tomography (CT) as the first-line diagnostic technique increased from 62.8% to 94.2% (P &lt;.001). Surgical treatment of type A AAS rose from 67.4% to 82.5% (P=.09). Mortality from type A AAS decreased significantly from 53.1% to 26.3% (P &lt;.001) as a result of the fall in mortality from surgical treatment (from 45.4% to 17.0%; P &lt;.001). The use of medical treatment alone for type B AAS decreased from 91.8% to 61.7% (P &lt;.001) due to the greater use of endovascular treatment. Mortality from type B AAS showed no significant reduction (16.2% to 10.6%; P=.15).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The diagnosis and treatment of AAS has changed substantially in the last 2 decades. CT has become the first-line diagnostic technique for AAS. In type A AAS, mortality has fallen significantly due to improvements in the results of surgical treatment. In type B AAS, the use of medical treatment alone has decreased due to the expansion of endovascular treatment, although in-hospital mortality has not decreased significantly.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Sociedad Espa&#xf1;ola de Cardiolog&#xed;a. Published by Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Evangelista</LastName><ForeName>Arturo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Servicio de Cardiolog&#xed;a, Hospital Universitari Vall d'Hebron, Institut de Recerca Vall d'Hebron (VHIR), Barcelona, CIBER-CV, Spain. Electronic address: arturevangelistamasip@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barrab&#xe9;s</LastName><ForeName>Jos&#xe9; A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Servicio de Cardiolog&#xed;a, Hospital Universitari Vall d'Hebron, Institut de Recerca Vall d'Hebron (VHIR), Barcelona, CIBER-CV, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lid&#xf3;n</LastName><ForeName>Rosa-Mar&#xed;a</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Servicio de Cardiolog&#xed;a, Hospital Universitari Vall d'Hebron, Institut de Recerca Vall d'Hebron (VHIR), Barcelona, CIBER-CV, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez-Lecoq</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Servicio de Cirug&#xed;a Cardiaca, Hospital Universitari Vall d'Hebron, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maeso</LastName><ForeName>Jordi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Servicio de Cirug&#xed;a Vascular, Hospital Universitari Vall d'Hebron, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellmunt</LastName><ForeName>Sergi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Servicio de Cirug&#xed;a Vascular, Hospital Universitari Vall d'Hebron, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf3;pez-Sainz</LastName><ForeName>&#xc1;ngela</ForeName><Initials>&#xc1;</Initials><AffiliationInfo><Affiliation>Servicio de Cardiolog&#xed;a, Hospital Universitari Vall d'Hebron, Institut de Recerca Vall d'Hebron (VHIR), Barcelona, CIBER-CV, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sureda</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Servicio de Cirug&#xed;a Cardiaca, Hospital Universitari Vall d'Hebron, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teixid&#xf3;-Tura</LastName><ForeName>Gisela</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Servicio de Cardiolog&#xed;a, Hospital Universitari Vall d'Hebron, Institut de Recerca Vall d'Hebron (VHIR), Barcelona, CIBER-CV, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonz&#xe1;lez-Alujas</LastName><ForeName>Teresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Servicio de Cardiolog&#xed;a, Hospital Universitari Vall d'Hebron, Institut de Recerca Vall d'Hebron (VHIR), Barcelona, CIBER-CV, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cuellar</LastName><ForeName>Hug</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Servicio de Radiolog&#xed;a, IDI, Hospital Universitari Vall d'Hebron, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sao-Aviles</LastName><ForeName>Augusto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Servicio de Cardiolog&#xed;a, Hospital Universitari Vall d'Hebron, Institut de Recerca Vall d'Hebron (VHIR), Barcelona, CIBER-CV, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Dorado</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Servicio de Cardiolog&#xed;a, Hospital Universitari Vall d'Hebron, Institut de Recerca Vall d'Hebron (VHIR), Barcelona, CIBER-CV, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferreira-Gonz&#xe1;lez</LastName><ForeName>Ignacio</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Servicio de Cardiolog&#xed;a, Hospital Universitari Vall d'Hebron, Institut de Recerca Vall d'Hebron (VHIR), Barcelona, CIBER-CV, Spain; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Epidemiolog&#xed;a y Salud P&#xfa;blica (CIBERESP), Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez-Palomares</LastName><ForeName>Jos&#xe9;</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Servicio de Cardiolog&#xed;a, Hospital Universitari Vall d'Hebron, Institut de Recerca Vall d'Hebron (VHIR), Barcelona, CIBER-CV, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Rev Esp Cardiol (Engl Ed)</MedlineTA><NlmUniqueID>101587954</NlmUniqueID><ISSNLinking>1885-5857</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000784" MajorTopicYN="N">Aortic Dissection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001011" MajorTopicYN="Y">Aorta</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057510" MajorTopicYN="N">Endovascular Procedures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute aortic syndrome</Keyword><Keyword MajorTopicYN="N">Aortic dissection</Keyword><Keyword MajorTopicYN="N">Aortic surgery</Keyword><Keyword MajorTopicYN="N">Cirug&#xed;a de aorta</Keyword><Keyword MajorTopicYN="N">Disecci&#xf3;n de aorta</Keyword><Keyword MajorTopicYN="N">Endovascular treatment</Keyword><Keyword MajorTopicYN="N">Imaging techniques</Keyword><Keyword MajorTopicYN="N">Prognosis</Keyword><Keyword MajorTopicYN="N">Pron&#xf3;stico</Keyword><Keyword MajorTopicYN="N">S&#xed;ndrome a&#xf3;rtico agudo</Keyword><Keyword MajorTopicYN="N">Tratamiento endovascular</Keyword><Keyword MajorTopicYN="N">T&#xe9;cnicas de imagen</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>2</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32499017</ArticleId><ArticleId IdType="doi">10.1016/j.rec.2020.02.015</ArticleId><ArticleId IdType="pii">S1885-5857(20)30180-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>